Podcasts about ADC

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:  Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities — Sequencing of ADCs and mechanisms of resistance (0:00) Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab — Richard Zelkowitz, MD (8:22) Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab responds to sacituzumab govitecan — Ranju Gupta, MD (26:43) Case: A woman in her early 80s with recurrent ER-positive, HER2-low (IHC 1+) mBC experiences disease progression on trastuzumab deruxtecan (T-DXd), then receives datopotamab deruxtecan and develops pulmonary symptoms — Laila Agrawal, MD (32:11) Data Review: T-DXd (37:51) Case: A woman in her early 70s with recurrent ER-positive, HER2-low (IHC 1+) mBC, including bladder metastases, experiences disease progression after palbociclib/letrozole, then capivasertib/fulvestrant, then nab paclitaxel — Justin Favaro, MD, PhD (44:02) Case: A woman in her late 70s with ER-positive, HER2-low mBC who experiences disease progression after 1 year of ribociclib/letrozole receives sacituzumab govitecan — Erik Rupard, MD (55:19) CME information and select publications

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

In questa intervista parlo con Alessandro De Concini, formatore ed esperto di metodo di studio, per capire come usare l'intelligenza artificiale nel modo giusto quando si studia o ci si forma.Scopriamo insieme quali sono gli errori più gravi che le persone commettono quando usano ChatGPT per studiare e perché rischiano di compromettere il loro apprendimento.Alessandro spiega perché l'AI dovrebbe essere vista come un tutor che ti affianca, non come uno strumento che lavora al posto tuo.Parliamo anche di scuola, del ruolo degli insegnanti nell'era dell'AI e di come il pensiero critico sia più importante che mai.Buon ascolto

JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, "Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for response to ICPI in mUC. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center. Today I am excited to be joined by Dr. Shilpa Gupta, Director of Genitourinary Medical Oncology at the Cancer Institute and co-leader of the GU Oncology Program at the Cleveland Clinic, and also lead author of the JCO PO article titled "Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma." At the time of this recording, our guest's disclosures will be linked in the transcript. Shilpa, welcome again to the podcast. Thank you for joining us today. Dr. Shilpa Gupta: Thank you, Rafeh. Honor to be here with you again. Dr. Rafeh Naqash: It is nice to connect with you again after two years, approximately. I think we were in our infancy of our JCO PO podcast when we had you first time, and it has been an interesting journey since then. Dr. Shilpa Gupta: Absolutely. Dr. Rafeh Naqash: Well, excited to talk to you about this article that you published. Wanted to first understand what is the genomic landscape of urothelial cancer in general, and why should we be interested in FGFR3 alterations specifically? Dr. Shilpa Gupta: Bladder cancer or urothelial cancer is a very heterogeneous cancer. And while we find there is a lot of mutations can be there, you know, like BRCA1, 2, in HER2, in FGFR, we never really understood what is driving the cancer. Like a lot of old studies with targeted therapies did not really work. For example, we think VEGF can be upregulated, but VEGF inhibitors have not really shown definite promise so far. Now, FGFR3 receptor is the only therapeutic target so far that has an FDA approved therapy for treating metastatic urothelial cancer patients, and erdafitinib was approved in 2019 for patients whose tumors overexpressed FGFR3 mutations, alterations, or fusions. And in the landscape of bladder cancer, it is important because in patients with non-muscle invasive bladder cancer, about 70 to 80% patients can have this FGFR3. But as patients become metastatic, the alterations are seen in, you know, only about 10% of patients. So the clinical trials that got the erdafitinib approved actually used archival tumor from local cancer. So when in the real world, we don't see a lot of patients if we are trying to do metastatic lesion biopsies. And why it is important to know this is because that is the only targeted therapy available for our patients right now. Dr. Rafeh Naqash: Thank you for giving us that overview. Now, on the clinical side, there is obviously some interesting data for FGFR3 on the mutation side and the fusion side. In your clinical practice, do you tend to approach these patients differently when you have a mutation versus when you have a fusion? Dr. Shilpa Gupta: We can use the treatment regardless of that. Dr. Rafeh Naqash: I recently remember I had a patient with lung cancer, squamous lung cancer, who also had a synchronous bladder mass. And the first thought from multiple colleagues was that this is metastatic lung. And interestingly, the liquid biopsy ended up showing an FGFR3-TACC fusion, which we generally don't see in squamous lung cancers. And then eventually, I was able to convince our GU colleagues, urologists, to get a biopsy. They did a transurethral resection of this tumor, ended up being primary urothelial and synchronous lung, which again, going back to the FGFR3 story, I saw in your paper there is a mention of FGFR3-TACC fusions. Anything interesting that you find with these fusions as far as biology or tumor behavior is concerned? Dr. Shilpa Gupta: We found in our paper of all the patients that were sequenced that 20% had the pathognomonic FGFR3 alteration, and the most common were the S249C, and the FGFR3-TACC3 fusion was in 45 patients. And basically I will say that we didn't want to generate too much as to fusion or the differences in that. The key aspect of this paper was that historically there were these anecdotal reports saying that patients who have FGFR alterations or mutations, they may not respond well to checkpoint inhibitors because they have the luminal subtype. And these were backed by some preclinical data and small anecdotal reports. But since then, we have seen that, and that's why a lot of people would say that if somebody's tumor has FGFR3, don't give them immunotherapy, give them erdafitinib first, right? So then we had this Phase 3 trial called the THOR trial, which actually showed that giving erdafitinib before pembrolizumab was not better. That debunked that myth, and we are actually reiterating that because in our work we found that patients who had FGFR3 alterations or fusions, and if they also have TMB-high, they actually respond very well to single agent immunotherapy. And that is, I think, very important because it tells us that we are not really seeing that so-called potential of resistance to immunotherapy in these patients. So to answer your question, yeah, we did see those differences, but I wouldn't say that any one marker is more prominent. Dr. Rafeh Naqash: The analogy is kind of similar to what we see in lung cancer with these mutations called STK11/KEAP1, which are also present in some other tumors. And one of the questions that I don't think has been answered is when you have in lung cancer, if you extrapolate this, where doublet or single agent immunotherapy doesn't do as well in tumors that are STK11 mutated. But then if you have a high TMB, question is does that TMB supersede or trump the actual mutation? Could that be one reason why you see the TMB-high but FGFR3 altered tumors in your dataset responding or having better outcomes to immunotherapy where potentially there is just more neoantigens and that results in a more durable or perhaps better response to checkpoint therapy? Dr. Shilpa Gupta: It could be. But you know, the patients who have FGFR alterations are not that many, right? So we have already seen that just patients with TMB-high respond very well to immunotherapy. Our last podcast was actually on that, regardless of PD-L1 that was a better predictor of response to immunotherapy. So I think it's not clear if this is adding more chances of response or not, because either way they would respond. But what we didn't see, which was good, that if they had FGFR3, it's not really downplaying the fact that they have TMB-high and that patients are not responding to immunotherapy. So we saw that regardless, and that was very reassuring. Dr. Rafeh Naqash: So if tomorrow in your clinic you had an individual with an FGFR3 alteration but TMB-high, I guess one could be comfortable just going ahead with immunotherapy, which is what the THOR trial as you mentioned. Dr. Shilpa Gupta: Yes, absolutely. And you know, when you look at the toxicity profiles of pembrolizumab and erdafitinib, really patients really struggle with using the FGFR3 inhibitors. And of course, if they have to use it, we have to, and we reserve it for patients. But it's not an easy drug to tolerate. Currently the landscape is such that, you know, frontline therapy has now evolved with an ADC and immunotherapy combinations. So really if patients progress and have FGFR3 alterations, we are using erdafitinib. But let's say if there were a situation where a patient has had chemotherapy, no immunotherapy, and they have FGFR3 upregulation and TMB-high, yes, I would be comfortable with using only pembrolizumab. And that really ties well together what we saw in the THOR trial as well. Dr. Rafeh Naqash: Going to the clinical applications, you mentioned a little bit of this in the manuscript, is combination therapies. You alluded to it a second back. Everything tends to get combined with checkpoint therapy these days, as you've seen with the frontline urothelial, pembrolizumab with an ADC. What is the landscape like as far as some of these FGFR alterations are concerned? Is it reasonable to combine some of those drugs with immune checkpoint therapy? And what are some of the toxicity patterns that you've potentially seen in your experience? Dr. Shilpa Gupta: So there was indeed a trial called the NORSE trial. It was a randomized trial but not a comparative cohort, where they looked at FGFR altered patients. And when they combined erdafitinib plus cetrelimab, that did numerically the response rates were much higher than those who got just erdafitinib. So yeah, the combination is definitely doable. There is no overlapping toxicities. But unfortunately that combination has not really moved forward to a Phase 3 trial because it's so challenging to enroll patients with such kind of rare mutations on large trials, especially to do registration trials. And since then the frontline therapy has evolved to enfortumab vedotin and pembrolizumab. I know there is an early phase trial looking at a next generation FGFR inhibitor. There is a triplet combination looking in Phase 1 setting with a next generation FGFR inhibitor with EV-pembro. However, it's not a randomized trial. So you know, I worry about such kinds of combinations where we don't have a path for registration. And in the four patients that have been treated, four or five patients in the early phase as a part of basket trial, the toxicities were a lot, you know, when you combine the EV-pembro and an FGFR3 inhibitor, we see more and more toxicity. So the big question is do we really need the "kitchen sink" approach when we have a very good doublet, or unless the bar is so high with the doublet, like what are we trying to add at the expense of patient toxicity and quality of life is the big question in my mind. Dr. Rafeh Naqash: Going back to your manuscript specifically, there could be a composite biomarker. You point out like FGFR in addition to FGFR TMB ends up being predictive prognostic there. So that could potentially be used as an approach to stratify patients as far as treatment, whether it's a single agent versus combination. Maybe the TMB-low/FGFR3 mutated require a combination, but the TMB-high/FGFR mutated don't require a combination, right? Dr. Shilpa Gupta: No, that's a great point, yeah. Dr. Rafeh Naqash: But again, very interesting, intriguing concepts that you've alluded to and described in this manuscript. Now, a quick take on how things have changed in the bladder cancer space in the last two years. We did a podcast with you regarding some biomarkers as you mentioned two years back. So I really would like to spend the next minute to two to understand how have things changed in the bladder cancer space? What are some of the exciting things that were not there two years back that are in practice now? And how do you anticipate the next two years to be like? Maybe we'll have another podcast with you in another two years when the space will have changed even more. Dr. Shilpa Gupta: Certainly a lot has happened in the two years, you know. EV-pembro became the universal frontline standard, right? We have really moved away from cisplatin eligibility in metastatic setting because anybody would benefit from EV-pembro regardless of whether they are candidates for cisplatin or not, which historically was relevant. And just two days ago, we saw that EV-pembro has now been approved for localized bladder cancer for patients who are cisplatin ineligible or refusing. So, you know, this very effective regimen moving into earlier setting, we now have to really think of good treatment options in the metastatic setting, right? So I think that's where a lot of these novel combinations may come up. And what else we've seen is in a tumor agnostic trial called the DESTINY-PanTumor trial, patients who had HER2 3+ on immunohistochemistry, we saw the drug approval for T-DXd, and I think that has kind of reinvigorated the interest in HER2 in bladder cancer, because in the past targeting HER2 really didn't work. And we still don't know if HER2 is a driver or not. And at ESMO this year, we saw an excellent study coming out of China with DV which is targeting HER2, and toripalimab, which is a Chinese checkpoint inhibitor, showing pretty much similar results to what we saw with EV-pembro. Now, you know, not to do cross-trial comparisons, but that was really an amazing, amazing study. It was in the presidential session. And I think the big question is: does that really tell us that HER2-low patients will not benefit? Because that included 1+, 2+, 3+. So that part we really don't know, and I think we want to study from the EV-302 how the HER2 positive patients did with EV and pembro. So that's an additional option, at least in China, and hopefully if it gets approved here, there is a trial going on with DV and pembro. And lastly, we've seen a very promising biomarker, like ctDNA, for the first time in bladder cancer in the adjuvant setting guiding treatment with adjuvant atezolizumab. So patients who were ctDNA positive derived overall survival and recurrence-free survival benefit. So that could help us select moving forward with more studies. We can spare unnecessary checkpoint inhibitors in patients who are not going to benefit. So I think there is a lot happening in our field, and this will help do more studies because we already have the next generation FGFR inhibitors which don't have the toxicities that erdafitinib comes with. And combining those with these novel ADCs and checkpoint inhibitors, you know, using maybe TMB as a biomarker, because we really need to move away from PD-L1 in bladder cancer. It's shown no utility whatsoever, but TMB has. Dr. Rafeh Naqash: Well, thank you so much, Shilpa, for that tour de force of how things have changed in bladder cancer. There used to be a time when lung and melanoma used to lead this space in terms of the number of approvals, the biomarker development. It looks like bladder cancer is shifting the trend at this stage. So definitely exciting to see all the new changes that are coming up. I'd like to spend another minute and a half on your career. You've obviously been a leader and example for many people in the GU space and beyond. Could you, for the sake of our early career especially, the trainees and other listeners, describe how you focused on things that you're currently leading as a leader, and how you shaped your career trajectory over the last 10 years? Dr. Shilpa Gupta: That's a really important question, Rafeh, and you and I have had these discussions before, you know, being an IMG on visas like you, and being in different places. I think I try to make the most of it, you know, instead of focusing on the setbacks or the negative things. Like tried to grab the opportunities that came along. When I was at Moffitt, got to get involved with the Phase 1 trial of pembrolizumab in different tumor types. And just keeping my options open, you know, getting into the bladder cancer at that time when I wanted to really do only prostate, but it was a good idea for me to keep my options open and got all these opportunities that I made use of. I think an important thing is to, like you said, you know, have a focus. So I am trying to focus more on biomarkers that, you know, we know that 70% patients will respond to EV-pembro, right? But what about the remaining 30%? Like, so I'm really trying to understand what determines hyperprogressors with such effective regimens who we really struggle with in the clinic. They really don't do well with anything we give them after that. So we are doing some work with that and also trying to focus on PROs and kind of patient-reported outcomes. And a special interest that I've now developed and working on it is young-onset bladder cancer. You know, the colorectal cancer world has made a lot of progress and we are really far behind. And bladder cancer has historically been a disease of the elderly, which is not the case anymore. We are seeing patients in their 30s and 40s. So we launched this young-onset bladder cancer initiative at a Bladder Cancer Advocacy Network meeting and now looking at more deep dive and creating a working group around that. But yeah, you know, I would say that my philosophy has been to just take the best out of the situation I'm in, no matter where I am. And it has just helped shape my career where I am, despite everything. Dr. Rafeh Naqash: Well, thank you again. It is always a pleasure to learn from your experiences and things that you have helped lead. Appreciate all your insights, and thank you for publishing with JCO PO. Hopefully we will see more of your biomarker work being published and perhaps bring you for another podcast in a couple of years. Dr. Shilpa Gupta: Yeah, thank you, Rafeh, for the opportunity. And thanks to JCO PO for making these podcasts for our readers. So thanks a lot. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Shilpa Gupta Stock and Other Ownership Interests: Company: BioNTech SE,  Nektar Consulting or Advisory Role: Company: Gilead Sciences, Pfizer, Merck, Foundation Medicine, Bristol-Myers Squibb/Medarex, Natera, Astellas Pharma, AstraZeneca, Novartis, Johnson & Johnson/Janssen Research Funding: Recipient: Your Institution Company: Bristol Myers Squibb Foundation, Merck, Roche/Genentech, EMD Serono, Exelixis, Novartis, Tyra Biosciences, Pfizer, Convergent Therapeutics, Acrivon Therapeutics, Flare Therapeutics, Amgen Travel, Accommodations, Expenses: Company: Pfizer, Astellas Pharma, Merck    

Antikörpertherapien gehören heute zu den wichtigsten modernen Behandlungsmöglichkeiten gegen Krebs. Um diese zu verstehen, tauchen wir deshalb in den nächsten zwei Folgen ein in die Welt des Immunsystems. Auf unserem Weg begegnen wir frisierten Töfflis, trojanischen Pferden, Antikörpern mit Boxhandschuhen und solchen mit Stoppschildern. Wir lernen, welche verschiedenen Antikörpertherapien es gibt und warum sie für so viele Menschen neue Hoffnung bedeuten.In dieser Folge stehen im Fokus: Monoklonale Antikörper und ADC's (Antibody-Drug-Conjugates).Diese Folge wird ermöglicht dank der Unterstützung von Amgen, AstraZeneca und GSK. Mit ihrer kontinuierlichen Forschung setzen sie sich für neue, wirksamere Krebstherapien ein und arbeiten daran, die Lebensqualität von Patientinnen und Patienten zu verbessern.Wir freuen uns sehr über Rückmeldungen, Ideen und Themenvorschläge für unseren Podcast. Schreib uns gerne auf Instagram (@lebenmitkrebs_ch), Facebook (@LebenmitKrebsSchweiz) oder via E-Mail auf info@lebenmitkrebs.ch. Alles Liebe Nadine & Sandra Disclaimer:Gekennzeichnete Folgen wurden mit finanzieller Unterstützung der jeweiligen Unternehmen erstellt. Die Unternehmen haben keinen Einfluss auf den finalen Inhalt der Folgen. Die Unternehmen sowie die Produzentin übernehmen keine Verantwortung für wiedergegebenen Meinungen und Aussagen von Interviewpartnern in den jeweiligen Folgen. Die unterstützenden Unternehmen und die Redaktion geben ebenso wenig individuelle Empfehlungen in Bezug auf die Diagnose oder den Behandlungsplan von Patienten und Patientinnen. Diese Fragen sind mit den behandelnden Ärzt*innen zu besprechen.

In this episode, we sit down with Riot Phroxzon, Lead Gameplay Designer at Riot Games, for a deep-dive into the future of League of Legends.We cover what Riot learned from the 2025 champion releases (Mel, Yunara, and Zaahen), why some designs missed the mark with players, and how those lessons are shaping champion philosophy going forward. Phroxzon breaks down Zaahen's kit design, community reaction to Mel, and whether Riot is satisfied with Yunara's long-term impact.The conversation then shifts to Summoner's Rift changes, including what worked, what didn't, and why Atakhan is being removed. We explore Riot's evolving vision for macro gameplay in 2026, including split pushing, objective control, and how the overall pace of the game is changing.We also tackle one of the most controversial topics in League right now: role balance. Why does Riot believe jungle is overtuned, why ADC and top lane are struggling, and how jungle lost its identity in 2025. Phroxzon explains Riot's internal data, the goals behind role quests, and what role balance will look like moving into 2026.Later in the episode, we discuss matchmaking and Solo Queue, including autofill philosophy, what it actually takes to climb, and how Riot plans to reduce time to get into games. We also touch on bringing back old items, Aegis of Valor, duo queue across ranks (excluding Korea), and what Riot learned from WASD movement testing.

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Please visit answersincme.com/860/IME-69386-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in NSCLC discuss how to harness targeted ADCs with practical, case-based insights to personalize care and improve outcomes in advanced lung cancer. Upon completion of this activity, participants should be better able to: Interpret the latest clinical trial data for approved and emerging antibody-drug conjugates (ADCs) in NSCLC; Recognize biomarker-driven strategies to guide treatment management in patients with NSCLC; and Apply evidence-based strategies for the individualized management of patients with NSCLC receiving ADC therapy.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal events and breakthroughs shaping the future of this dynamic industry.The pharmaceutical and biotech sectors are experiencing a wave of significant advancements, regulatory shifts, and strategic maneuvers. Recently, Bristol Myers Squibb faced a delay in their Alzheimer's psychosis treatment, Cobenfy, due to site irregularities detected in the ADEPT-2 study. This highlights the critical importance of rigorous clinical trial management. The postponement could influence stakeholders' confidence in timelines for breakthrough treatments in neuropsychiatric disorders.Richard Pazdur, M.D., is preparing to retire from his leadership role at the FDA's Center for Drug Evaluation and Research. This transition period could have profound implications for how new therapies are evaluated, potentially altering approval processes and timelines. His departure marks a significant shift within an agency renowned for its role in drug approvals and regulatory oversight.On the scientific front, Cosmo Pharmaceuticals has reported promising results from two Phase 3 trials of clascoterone, a topical cream designed to treat male-pattern hair loss. The findings suggest that clascoterone could become a transformative treatment by offering a novel mechanism to address androgenetic alopecia through the inhibition of dihydrotestosterone activity at the follicular level. This development underscores an expanding focus on dermatological conditions within biopharma research and offers new hope to millions affected by hair loss.In legal developments, Daiichi Sankyo's successful appeal in its antibody-drug conjugate (ADC) patent dispute with Seagen marks a significant victory with substantial financial implications. The overturning of a $41.8 million verdict illustrates the competitive dynamics in ADC technology, which plays a crucial role in targeted cancer therapies. This case emphasizes the importance of robust intellectual property strategies in maintaining competitive advantages in innovative therapeutic modalities.On the funding front, Excelsior Sciences has secured $95 million to enhance its "smart bloccs" platform for small molecule discovery and production. This investment aims to support advancements in chemical synthesis technologies crucial for accelerating drug development pipelines and fostering collaborations across therapeutics and materials science sectors. Such initiatives underscore the growing emphasis on technological innovation to streamline drug discovery processes.The European Union is making strides toward bolstering supply chain resilience with new regulations aimed at preventing drug shortages. By diversifying local biopharma supply chains and encouraging domestic production, these measures address vulnerabilities exposed by recent global disruptions. This policy shift could lead to more sustainable drug manufacturing practices within Europe, ensuring better preparedness against future crises.Pharvaris has achieved a significant milestone with its Phase 3 trial of deucrictibant meeting primary endpoints. This sets the stage for regulatory filings as a competitor to KalVista Pharmaceuticals' Ekterly in hereditary angioedema treatment. This progress highlights ongoing innovation in addressing rare genetic diseases and fostering competitive therapeutic landscapes.The FDA's approval of Cleveland Diagnostics' IsoPSA test marks a notable advancement in prostate cancer diagnostics. By detecting specific PSA protein variants associated with malignancy risk, IsoPSA represents a step forward in precision medicine. It offers enhanced diagnostic accuracy and potentially improves patient outcomes through early intervention strategies.Overall, these developments reflect the dynamic nature of the pharmacSupport the show

Now, and??? Okay! Just another dime, And just enough to find Before I count them up to dollars— But you're turning into wine. What did you ever want? This is my other world. Go shatter you tantric catwalk elsewhere! Don't you know there is a show to put on? A wool to pull over the eyes of the unknown? Why do you have to groan at the quantifiable harm known but justice undone. No harm, no foul No food, no valid excuse for betraying my sacred dopamine, but hopefully you know only no good But words can come from it, And words that fall on blind eyes have no context at all. {Enter The Multiverse} Uncorrected transcript. [excuse my neighbors in the background they're determined to make my life miserable more than likely in exchange for dollar signs.] Okay, my Wi-Fi is off, my Bluetooth is off. Oh, my laptop is open, my Wi-Fi is on. I can give me a second to remedy that. Hello. Hello. I'm Atticus's tail says hello. What's going on? Oh, I wasn't planning on oh, my WiFi on my computers off. That is good. Uh, I keep all my devices uh, at minimum on off the grid as often as possible. Um, there there actually it's crazy how much of a difference this makes. I gotta pour myself some coffee. it is almost midnight, o'clock. Hello, um, what's up, we're missing talking episodes. Um, we're missing talking episodes from season 12. I can't find anything like past October, and I know it's on one of my hard drives, but all of my hard drives are full, um, I have like something like 10 terabytes altogether of stuff that needs to be like moved around and not all of it. Some of it's like really personal, like not personal, but like sensitive information that I can't necessarily utilize a cloud for. So I am it's taking me some time to organize some stuff. I I try to do between like eight and 12 hours of just organizing on any typical night after my uh exercise or whatever, or between I would say that exercise is definitely like the primary function of like my life. And that's like the priority right now, especially with the things that I've been going through. I think it's really important to keep my physical and mental health as um in in it's not gonna be at its peak, um, because of the noise pollution that I've been dealing with, and it's actually made me really sick over this extended period of two times. um, and I'm trying to um seek treatment for that, but it's a uh it's a long road, I have a long road ahead of me. We could just say that. Um, which is why I am giving you guys, um, some stuff that I've been working on that's not necessarily finished, and I'm actually really like, I'm embarrassed because I don't necessarily um I I actually have a hard rule of not releasing any music until it's absolutely finished. like even if it is a first draft, like it still has to be finished. um, but I actually and I gave you, I think, I think two tracks, which is actually four. um because this upcoming project, it's a concept album called a symposia. um and the concept for it is um a lot. I don't necessarily have to explain right now. Um, but all of the tracks so far on it are double tracks, and so it is typically I've always really loved albums that have that are like gapless. I don't think through my distributor, like I can never technically um, like put out an album that has no um technical stop or start between songs, like they would have to be cut a certain type of way that, like my distributor does it. There's always gonna be a gap between my music, but um all of the tracks are um double tracks, so they're all two tracks in one, um that are kind of along the same theme or idea and um like lead into the next track. I've always loved albums like that. uh, one of my favorite compilation albums, um like just to give you an example, just to throw it out there, is like, the Beatles love album, which is not actually a Beatles album. It's just a, um, it's a compilation of their um songs made for the Cirus Sole show that I think is still playing in Vegas. I don't know if it is it's been playing for like 10 years, and I still haven't seen it. um I really I really want to take mushrooms and go uh see that show. I've wanted to do that since it came out, but my favorite one of my favorite albums in the world is the love album, which is is basically a mash up of like their greatest hits, crafted by, um engineers and people who used to work with the Beatles and stuff for this uh Cir dis soet show um in Vegas that I hope I get to see I hope it's just one of those like long standing like like Siegfried and Roy. I just realized that they were in Vegas for like 40 years, like they were just there, they were just a stable, so hopefully that show is um kind of like that and one day I'll get the, uh one day I'll get the opportunity to see it. Like my my bucket list, like destination, like vacation at one point was to go see the Beatles love on like an EDC week. um that's still something that I want to do. I promise myself I wouldn't go to EDC unless I like ever got booked there. Um, and I think this year is like 30 years or something of EDC, and so they um they sold out in like five minutes. um so it's it's not it's not something I'd consider doing by myself anyway, unless I was gonna go with my best friend, and um and I was like I was talking to my best friend and I was like, oh, maybe I should check on, like the early bird tickets for ADC, and they were like, they was sold out, and was this celebrating 30 years, and I'm like, okay, well, I guess I should uh work on getting a booking agent, but my music is not my music is kind of turned into like a passion project. um, since everything that I've been going through over the last couple of years kind of just like took me off my path in that sort of way and DJing, I kind of wanna preserve it as like, I really love being a DJ. I really love producing music and because it's so consumer, there's a bunch of people in the industry that are not necessarily like music oriented or love oriented, and it's just like a whole different vibration from like the peace and the love and the unity respect of that. Like I like the scene for. I really want to check out, like as far as a festival goer is concerned, I really wanna check out some of these new festivals that are popping up that are doing like no cell phones. I kind of wanna check those out, cause I feel like the quality of of the experience has been preserved or will have been preserved in in certain spaces like that, um, but anyway, I'm uh I have been physically ill for like a few months now. um, and so the best that I can do for you guys my audience just because I'm not sure if I will get symposium out this year in which case it will come out next year. um, and then I think this track, I'm not sure, this track is definitely like a track that was in my mind. um implementing all of the like sound design stuff that I'm doing for symposium and is also a double track. um it's called Forget me nots. uh and then the second track is followed through. uh,get me nots/follow through. I think it's like an eight or nine. um minute track or whatever. It's not finished. Um, actually, the only finished track that you guys have heard, and even this even bitter butter and southwest of your scars is like a double track that is finished, that is on symposium, but it's still the version one, like it's not um I haven't done like any of the final mastering or any of the things that I do in the process of getting ready for a a release. I do have like a a like an implemented ritual structure of doing things like that, even for projects that seem like mindless, or, you know, things that are seem seemingly just like thrown together, like chasing dragons, was kind of like not necessarily even a concept until the three tracks were like sandwiched together, and I was like, oh, okay, like, this does tell a story and and they were all created in a certain way so that they'd go together. I think I fixed that. um, because, um, chasing dragons, the EP was for some reason, when chasing dragons got released to, like all the major platforms, it had chasing dragons was the first and the last track, and then dishes and the sink was just in the middle, which was weird. um so the third track on chasing dragons is actually immortalist and I got that all fixed. and I also got the regular like the normal version of the songightfall is out on the platforms now. Those were two er errors um that I needed to fix that I finally did. um but I'm slower to do music things now because like I said, my health is the priority. So it's like, yo, if it comes down to like getting a good meal in or like some good exercise or like right now I'm doing active recovery because I'm dumb. I went from like not really running anymore and only walking for an hour every day on the treadmill and doing like an hour between one and two hours on the pelotone, a day which is technically still three hours of work, um, but then I went back into heavy training the way that I preferred to do like I prefer to be at the gym between two and three hours every day. That is my ideal. That is where my body feels comfortable, um and flexible and like happy. Um, and if I can do that in the very beginning, like to start my day, cause I don't necessarily have 24 hour, like days anymore. um like what's technically the end of my day is oftentimes the very beginning of other people's days, and so I'm kind of just on on night, like, routine because it is like, I'm I'm basically just like protecting myself from the uh, you know, like my my nervous system can't take any further damage. Like, I do have really pronounced synesthesia and, um, I wasn't necessarily like planning to be exposed to extreme like noise pollution for an extended period of time without having the financial security or stability to escape from it, cause honestly, if I could have moved, I would have moved or if I could have just left, I would have just left, um, but I obviously wasn't in a situation that I could, and so I became very vulnerable um, to this type of attack, which I learned was actually very common. It's not something that is just like, oh, you know, um, this is just something that I'm going through. It's actually a very common for people of color to be, um vulnerable to this kind of disease that comes from um an implementation of using sound as a weapon. And I mean, like the irony is is that I was already kind of studying synesthetics and the way that, you know, as a culture or the way that in as as far as like mass consumerism is concerned, that's why people pay so much for a, you know, festiv for the festival experiences because sound can be a very much uh manipulated to be a physical thing. It's not, you know, it's not invisible. And so the fact that those same kind of um those that same kind of engineering can be implemented also in a negative way to have a negative effect. Like, you don't have to punch somebody in the face, like, you can just back up your exhaust, your engine exhaust, and, you know, fire at point blank to somebody that is, you know, caught off guard. and in that way, um sound can be used as a weapon, it uses the same dynamics, the same kind of dynamics as, you know, the reason why we go in the th you know, in flocks by the thousands and the millions to these festivals to feel the vibrations that that are on the opposite end of the same spectrum, the healing vibrations of, you know, certain things. and so I've been doing my best to try and, you know, maintain a certain level of health through, you know, using, um, you know, certain frequencies to block out. But when it's your physical person is in a space that's being manipulated to be on a certain frequency, um, uh, the exposure to this negative frequency that is unnatural to your body over a period of time. um, you begin to get very, very sick and that's what's happened to me. And so I'm trying my best to like keep my head above water and, you know, stay afloat. Um, but I didn't expect it especially after, you know, a period of like two or three years before that, where I was just like on the go all the time. Um, and, you know, not necessarily having like a a suitable foundational stability or a place to call home and then going straight into something else that was like more traumatic and more violent than, um then I expected, and so I've been trying to remedy that. um, the best that I can and because I'm putting my mental health and my physical health first, I'm not necessarily like, I it was weird. I was kind of in like a meditative space and I had, you know, like this this kind of spirit come over me that was like music, you know, music is gonna be there forever. like, as long as you're as long as you exist, you know, whether it's in like a physical realm or like an infinite realm or whatever, like as long as you exist, there's always gonna be music. and that was kind of like the sign that like, K, as much as I do like having a streak of, you know, like being an Ableton every day for several hours a day. um, the way that I am using these techniques that I'm applying in symposium and as seen on TV, which reminded up being a double album, because I actually have, um, like several, um, tracks that are like honestly on TV, I've been working on since, like, 2023., like, early 2023. Um, and so, the things that I've like collected, it's kind of interesting because my evolution as an artist or like my technique as a producer will be, um represented here in this project, which I hope comes out next year, but I can't say for sure, cause it's probably the it's definitely the biggest, most um important album I've ever worked on and I I put a lot of care and thought into those as seen on TV tracks because it does um like creatively, I guess, run alongside this series into the multiverse and all the series within the festival project, uh Ascension Death Wish, legends, um the legend of uh, the secret life and the sweet life of sunny Blue, just to name a few, there are I keep trying to make like a list of all of the shows within the festival project, but then I'm like, oh, like there are so many that it would it just falls apart. And so I mean like I'm getting a little bit more organized with the with the actual structure of, like, the television and movie, like, script part of the project. um, while I'm cleaning out my hard drives, but having to organize everything so that it's, you know, so that I can go to a certain hard drive and be like, okay, well, this is um, you know, this is this season to this season. I'm still archiving episodes from, you know, 2021 and and because a lot of those statistics can't be like once I delete an episode from the podcast, it goes away and all the all the statistical information about the number of downloads,, like all of its information, all of its metadata goes away. and that's very important for what I'm going through in my personal life right now in order to protect myself for those things to be taken down, but also for it to be archived in a way that I can reference as a creator like, okay, this is this day that this was published with this, that like, because it's it's a time travel concept that is multifaceted, and it is like based in this multiperceptory m multiperceptory multiimensional concept of technically technically infinite time and space, like it has to be organized in such a way that, like, all of the series and all of their all of the ways that they're connected to any particular parallels have to be, you know, they have to be organized and documented so that because I'm the more that I'm looking at it, the more it makes sense. I'll be like, oh, like, I thought this was just like nonsense or whatever, but when I'm putting it into like an organized space, um, and to me, that's like the god part about it is that like, oh, like, um like, I' I'll be looking at the writing and noticing how it takes like particular shapes or how the shapes will cut is sometimes like make pictures, like sometimes when you're looking at the clouds and you see, you know, shapes and the clouds. sometimes the riding for this project is like that, which is kind of incredible to me.c it's not something that I'm doing um, intentionally, it's kind of just something that's happening. I'm writing in a stream of consciousness that's also, you know, like artistic, creative in a way, that kind of has this, like, sense of divinity to it that I'm not necessarily, like, consciously doing. Um, so everything has to be organized in such a way that like it is gonna take time, um, and because it takes time and a lot of the other things that I did not foresee happening or also taking a lot of my time, like a lot of my my time and energy to document like how sick I've been getting a lot of time and energy has been focused on just like, doing the research on, you know, like crazy crazy shit that I never really took interest in, um, but could be applied here. um, could be applied to this situation and and kind of just finally being able to have a piece of mind to give myself the benefit of the doubt that, like, it wasn't in my head. like, I just had to be uh, I just had to be pushed to the point that I could understand, you know, that this um, sometimes very silent type of, um, you know, warfare is is like a documented not even necessarily historically, but like presently and present day. um, they're just I don't think haven't been enough survivors of this kind of thing, um, that it could be, um that it could be notably researched, like the amount of reports, but, you know, it's it's not it's not by choice, like it is taking up a lot of my time and I wish I was the kind of person that could just ignore it. Um, but I'm getting very physically ill. Um, so I can't, like, I can't ignore the fact that, like, you know, I'm running on zero pretty much all the time, and that my my patterns of speech have changed in my, you know, my thoughts have been intercepted and my, you know, like, because physical and mental health is such a priority to me, the fact that those things have been the primary uh, source of degradation has has affected me in such a way that it's not, I mean, like, it's less emotional than it is the logical answer to, you know, like if you have a cold, you take cold medicine or if you have the flu, you take, you know, it's it's like, well, remedying something that is a fi physical illness, you know. um, removing the cancer from the body, uh, you know, in such a way that it doesn't come back is kind of my main primary concern in this way. Um, so I am am especially because I can't but the talking episodes are actually more popular this season than any other season. and I can't find like six or seven of them, because I I don't know, I was just switching out all my, you know, uh my stuff so quickly and pulling things out of the cloud that it, you know, got saved under drive zip eight, seven six nine, you know, like. It's it's just a mess of of terabytes and tabyrites of creative work, um, and, you know, other things that I've had to dedicate my time to, which is not necessarily fair, but, you know what they say is life is not fair. Um, so, you know, life hasn't been fair, but I have, you know, been blessed in such a way that, like I I I've at least been able to um creatively channel some of the some of the energy and some of the time that I have left over that is technically mine. while in the sense that I've had a lot of my time and energy just stolen in siphoned, um, you know, I have been able to kind of forge a medium through fighting this that allowed me to, you know, start doing art along the lines of, um more more the way that I want my music to to think and feel. And so I'm I'm still just working from a little tiny MacBook air. um, so my, you know, um, my projects get like overwhelmed really quickly. I can't necessarily implement all of my um my plugins or all of the tools that I like to use at once, and so everything is kind of segment segmented in the way that I'm working. um and like, yeah, my projects get overloaded very quickly. um so the tracks that I'm giving you are not finished, but they're more um I would say like they're more, like colored, they're more like filled out. It's not necessarily abstract in the way that some of my stuff is like very like, you know, like drag and drop and cut and go, well, I do a lot of like, even in my even in my like my cut and dry stuff, I do a lot of sample manipulation. I very rarely will keep a sample in the way that it is without doing something to it, you know, like, I don't do dragon drop, um, unless I'm planning on just, like, you know, giving a beat to a rapper a artist for free. like, sometimes I'll just be like, okay, for the next 15 minutes, just do, like, something, you know, like a two or three minute, like dragon drop or whatever. But those those are not necessarily tracks that I A share here or B like plan on doing anything with because the world of sampling has gotten to the point where it's like, yo, you gotta have some creativity, like you can't just open up a sample pack and drag it and drop it into place, because then you have eight or nine songs that sound exactly the same. Eight or nine songs that are the same because basically you're just putting together a, you know, you're putting together stems from a track that was already created, you know, by somebody that's trying to sell you something, so um, you know, I I take a little bit more creative uh integrity in the stuff that I do mean seriously. Um, a lot of it lately hasn't been serious, but I I actually did want to take an hour to talk about this not this track in particular, just talk about why I'm doing this because it was something that it was like, oh, I feel like this project is a little bit more special or is a little bit more like technical than some of the other work that I've shared here on this podcast or work that I've put out before and so I kind of wanted to keep it to myself um, but then I've kind of had a couple, like, you know, like heart shattering experiences that make me realize, like, you don't know. like, you don't really know what's gonna happen and life is, um, sometimes very cruel and sometimes life is, you know, it just takes turns that are not necessarily. um you know, like you don't you don't ever know. And my mindset has not necessarily been that negative. It's like, oh, everything, you know, there's a there's a reason for everything, and blah, blah, blah, and I still do believe that, but like, you know, two years of constant, like, torture and stress to the point where I don't necessarily have a medium for support or, you know, um, like, I don't necessarily have the foundation of community. um, being in a place that is not my home and coming from a family that's very, very small and doesn't necessarily have, you know, well, like, I don't have what some people have, I don't have a large network of family and friends and the kind of family and friends that you create for yourself in the business are not necessarily, um, you know, like people can't necessarily be trusted to have your best interests. Um, especially especially if you are coming from like a a margin for success that, you know, is documented, like you've done well, you can't necessarily still believe that, like, everyone in your immediate circle has the best interest for you, because it is in human nature that everybody has, you know, themselves as the primary interest, and so um, me being like a a solidly um you know, like self sufficient. I won't say independent person. um, driving towards independence or whatever. um, but being a person that spends a lot of time in solitude and with enough respect, like enough self-respect to understand what my when my spiritual and my personal boundaries are being pushed even even in a person you know, professional setting. um like I took today for active recovery because I'm dumb and I went straight back into training as if I'd never really stopped. like it okay, like I'm on the Peloton seven days a week and I have a treadmill that I walk on in for an hour a day, you know, five to six days a week, but it's not the same as like being in the gym and lifting in stri strength training and and um active recovery um but I was like, okay, if I was running like a Madonna or whatever, you know, for this amount of time, then I should be able to do that. I should be able to do that. No, I didn't run a Madonna, but I ran like a 3K and then a little bit. and I like, my body was like, yeah, this is good, but then I had, like the rest of the day and I did not properly hydrate, and I got, like even more sick. and so I'm like, oh, fuck. Like, I really got like I really got a prioritize, like, my physical health, because if I keep letting myself get pushed, you know, like over the summer, before requisite when I was just like, oh, you know, like, I'm just gonna record. I'm gonna go to Manhattan 20 fucking days in a row and not take a day off and I'm also gonna train, you know, and I'm also gonna do this, like the like, I'm maximized my potential for burnout, which also left me per like, personally vulnerable. to the, like, professional sabotage and, like, weird, underhanded, like, underbelly shit that, like people in the DJ circuit are doing because it's so hard to actually break through., from the level of like consumer professionalism right now. So people are doing like a lot of nasty things to try to get that main stage spot and I wasn't like in my head, I'm still very much like a Disney kid, like, I'm still like, I don't necessarily well, I mean, like Disney to teach us like, there's always gonna be a villain, but like, a society kind of undoes that teaching and is like, but that's just in movies and that's just in your head, but there's no like to me, I there is just this weird misst up between real life and what is told that like, okay, like anything that exists that is like in a certain field of negativity is just in your head. but, like, evil is it like a documented source of the opposite of good. since the beginning of time, and I just don't understand in how in a society we can philosophically and psychologically embrace therapy, however, when it when it comes to, like, real lived experiences, when you're dealing with something that is not necessarily, uh, like a normal part of societal living, like that stuff only happens in movies. I'm like, but it does happen. Sometimes you just have to, you know, like being having I've I've never really been such a socially dependent creature. like, a lot of people have to have some kind of validation. That's why social media is like ruling our society right now. is because people have to have the validation or the likes of whatever they're doing is like cool with the rest of the group. and to me, that this is dangerous group think. like, if you're all thinking the same way, then there's something being missed. There's always something being missed, you know, if you're all on the same frequency or the same form of thought, you know. And so, I've always been like a big, you know, maybe it's just because I don't have any siblings. I've been like a big believer in embracing, um, independent thought, like, okay, if everybody else is thinking one way, then what is the opposite of what everybody else is thinking and not necessarily alluding to the fact that the opposite might be the right thing, but anything between whatever the group think and the opposite is, is also like valid, could be valid, you know, it's not necessarily the opposite of what everybody's thinking, but it's somewhere along the spectrum of maybe that or maybe the opposite, like it could be anything else in between. And so I think I'm the kind of person or the kind of thinker that's motivated by the the spectrum, you know, the spectrum, uh process, anything in between, like not necessarily that, not necessarily the opposite of that, but like what other possibilities, you know? um, could be validated or verified through thinking outside of the box or outside of a you know, being forced to the point of conformity that, like, everything sounds the same and everything looks the same and everything has like a way. That's not necessarily wrong. um, but also not necessarily the only way or right. um, so that I' of been uh what what did I get on that round about? I don't know. I've just been playing with like a lot of different concepts, like not necessarily trying to sound like anything. or anyone, and also not necessarily having the opportunity or environmental expression, like the space to be able to sound like myself. Like I still don't artistically or musically think that I sound like myself. um, and that they are elements of myself there, but it's something that's kind of, um, in its, you know, convex form of being this thing that is potential, but not necessarily fully realized or realizable yet. Like, I haven't had I haven't had peace and I haven't had like full p I haven't had peak health in a long time, or a safe environment in a very long time. and I think that the disallowance of comfort, not necessarily the safity of um of complatancy, you know, or or being comfortable to a point that it's it becomes dangerous, um, but just being able to kind of be in a life that is not necessarily like violent or terrible all the time. I think removing these barriers has not necessarily been a foreseeable reality for nearly a decade and while some artists technically thrive in what is, you know, what is this, you know, tragedy and darkness? It's there's only so much of a certain space that my creative ingenuity can take up and not void. And so, understanding that this time is kind of transitional in the sense that eventually it has to in no matter what direction break free from its current state of, you know, entrapment and its current state of imprisonment. um and so in my artistry and not will change, but I don't think I don't think it's necessarily going to be like fully realized until I have a a a point that I'm in an environment that I can breathe and be and think clearly without the force of control or being subjugated to, you know, a certain level of violence that's not necessarily always physical, but is certainly not, um, you know, without it's notable, um, impact on my physical health, my physical and mental health. So that being said, um, this track, um, this track is somewhere between symposium and, um, as seen on TV, I think I began writing it before the concept for symposium was fully formed. and, um, I think it was like the first of its little group of double tracks and I didn't necessarily mean, like, for the story, cause it, you know, ideally, like a song is like five minutes or less or whatever. um five minutes or less or whatever, but I've again, not been, uh, trying to conform to what is supposed to be this, or what is supposed to be that, and, um I don't know. I I began writing it in with the mindset and the technicality of symposium, but also as I listen back to it, um, I'm also using elements that have been implementing for the last few years into as seen on TV. And so there's some like to me, it's very beautiful. Again, what what is more important or more, you know, like wh what is more palatable for my audience is always differed like my favorite tr tracks are not your guys's favorite tracks from what I'm looking at for for the numbers, you know, my favorite episodes of me talking are not your favorite episodes for me talking. So, I mean, like they're exists here, this obvious, like, it's weird because a lot of artists can be applied to their fans and to their listeners. It's like the the listeners are being projective of like they see themselves in their favorite artists, or they see themselves reflected back through an artist that they, you know, like Taylor Swift, like, all her fans are Taylor Swift and like, most artists are that way that, you know, they're reflective of the people that they look like and have the same experience of and that's how, you know, um, that's how mass that's how mass media works. It's reflected, you know, through the medium of sorts, you know, um it as a as a concept that is shared amongst all all of those, you know, people. um, but I'm looking at my numbers and I'm realizing that, like, oh, there there's like a distinctly different flavor from the way that, like, my perception of what is my best work is and what my audience thinks is the best or, you know, the like I look a lot at the numbers not as they happen, but like over time, whereas I'll be in hiatus for a certain amount of months and then I'll come back. and see what the numbers are reflecting in in what is more, you know, palatable for my audience, like what my audience is is actually agreeing with more is like my better work and it's always not it's not necessarily again, it's not necessarily opposite. but it's not um, you know, it's not always what I expect to be. So this to me, I like um, but it doesn't necessarily like that you, whoever you are as an audience is gonna agree. Um This is actually the least completed track. um I feel like I'm showing you yeah, like I'm showing you my my uh it just it's naked cause it's very much not done. This is probably the most incomplete thing that I've ever, like, put out for anybody else to listen to. Um, but just being audit honest as like a person, not like as a entertainer, cause I don't necessarily see myself as that anymore after these couple years. Um, but being honest, like as a human being, as like a person, um, I've had some times that feel as though are, you know, an indication of not having a very prolonged experience in this sort of way. And I don't, like, I don't wanna put a trigger warning on anything. And I don't wanna, you know, like I I also don't want to insinuate things that are not there. Um, but a lot of the time, that is just to say that I don't feel safe, um, that I don't feel, um safe or secure, um, and that there's not necessarily a like sh it's just New York City. There's no level of like autho like a there is no necessary authority complex that has any sort of like, ability to protect you, you know, from uh certain experiences that are not necessarily um, you know, there's there's no level of protection from from, you know, there there are more heavily funded organizations that are like banks and investments or are more funded than the police. So when you're telling the police, like, hey, I'm being, you know, stalked or harassed and like, there's a pattern and like, here's the evidence and they won't even look at your evidence. Um, even though technically by the law, like it is, you know, documented uh, verifiable, like verifiable, like, no, there's none in my head. Like, I have like the videos, I have pictures, I have audio recordings of like this is happening to me, and they won't even look at it, um, not necessarily because they don't want to, but maybe because they've been trained to look in the other way. Um, and then, you know, just the cultural disadvantage of like, youre snitch. I'm like, I'm also within inches of my life sometimes. and nobody's helping me. Um, and it's not necessarily a mental condition. I think that more now than ever, I would be like readily willing to admit like, oh yeah, like, I should just take the meds, but I'm like, this is I'm not hallucinating this. I'm not gonna take some kind of fucking pill for some kind of medication for something that's like, I'm experiencing this, and not only am I experiencing this with like my eyes, my nose, my ears, like, I'm now videotaping 100% of my life everywhere I go. If I walk out the door, I'm recording, like, that's how many times I've been stalked or followed. Like, if I walk outside of my apartment, like I'm I'm videotaping it, because if I don't, if something happens, then it's literally their word against mine. and the police is, like, literal their whole thing is like, if we didn't see it, it didn't happen. Like, you can get you can get, like beaten within an inch of your life and the police can show up and you can tell them and they can see you like bleeding from the face or whatever, and be like, that guy did it, but the police will straight up tell you. the police will straight up tell you like if we didn't see it, it didn't happen, like we can write the report, but like we like they will not investigate. Period. They will not investigate. And so understanding that, like that opens the, you know, the possibility of like way, way more heinous crimes, you know, being able to be, um, played out without, you know, without any possibility of you having help for that, as, you know, is like dangerous to me, and a lot of the time I feel like I'm in danger, um, to me, and so, my priority is not sitting down in Ableton and and you know, getting these cues just right, like, especially with this this track. um, like it's so, so far from complete, but when I hear it, it still sounds it sounds decent enough that, like, I'll give it to you guys just in case, like like the least sometimes that I feel is gonna happen is that I just get hit by a bus. uh, which does happen almost any time I go outside. It's like, I will not get a bicycle. I won't because I'm like, that's like the easiest way to ensure that I will get hit by something. I'll get hit by something. um I will get hit by something, so I don't um I don't, you know. I'm just trying to, uh, get along and protect myself and away that, you know, maybe possibly enables me to, like, disappear. I don't necessarily need to be anybody. I stopped fighting for that main stage spot a long time ago, cause I I see that it's not about like it can't necessarily be about the love when it's about the money. and I have so, so much love. like for the music, um, and for what used to be the scene. I mean, the scene's always been kind of dirty. You pick up any book about DJ culture, about festival culture, you know, about music in the in the sense that it's been meant in the rave world has always had like a CD side to it. um because it was previously a counterculture, you know, that became mainstream and it still definitely has its like flavor, it definitely has its like, you know it's flavors to it, which, you know, is is a magnetism or like a draw, that's like, oh, there is this darkness that exists, but like, at the core of it is the frequency, you know? And I think that if there was ever going to be like a place for like a placeholder for success for me and the industry, it would be somewhere in the future when it can be a more decisive. No, what am I trying to say? Oh, I don't know. I think that money really fucks things up sometimes, and because of the amount of inequality in the world and the fact that the the world has become such a competitive space, um, that there're actually less places for opportunity for artists, even though it seems like there should be more. um I think until it's like about wellness, yeah, I think in until music can be until we can create like spaces where wellness is like at the center of these, you know, gatherings, then I don't think it's necessarily going to be like a safe place. Um for anybody, but let alone for me, because I'm very much like a fragile person when it comes down to, um, like per like the protection of my spirit and the protection of my aura, I don't necessarily want to be in a place of uh tragedy or a place of defense all the time. I I wanna go outside and and be in defense mode 100% of the time. I am right now, so um, like anything I I I kind of take it with a grain of salt in the way that like anything I say can and will be used against me. And so I don't say so much. I I don't say so much, and I want to be sure to take care of my art in a way that it doesn't is not, um, you know, so that it doesn't necessarily exist in a place of toxicity or that it's not coming from. Like, I won't sit down and Ableton if I feel a certain way. It's not just me being lazy. Like it's if I have like a certain vibration that's incurable, like it's not uh it doesn't make sense for me to, like, you know, sit down and work on a track. So this this track, uh, forget me nots and follow through. um, I think it is the first track and symposium. I don't know, because when I listen back to it, I also hear um when I listen back to it, I also hear as seen on TV, like a lot. um like a lot. And so it's kind of interesting to see those two kind of elements of my artistic personality combined, because I think the tracks that I've shared with you that are from symposium or different in the way that they're um made only one way, but this one is definitely implementing um techniques from two projects. Um, so the what are the two other ones? I think it's like talked to me about it. Is that oneosium? I think so. and bitter butter and southwest of your scars. Ah, those are all from this project, but then I I look at this one, which is technically the first of the bunch and it's so not done. that I'm like, don't put it out until it's done. and I'm like, well, and might not ever be done with the shit that's happening is kind of scary. Like, it's I might I may not ever be able to get back to a place where this is possible because of the things that are continually happening uh, to me. Um, I I don't know what the source of evil is. Like, I really don't, like I am very much a spiritual person and I do have like the tendency to believe that like no matter what God has my back so if I'm removed from one situation or existence into another, it is for the protection of that aura, for the protection of that frequency, for the protection of, you know, keeping my, you know, um my source intact, like there's, you know, certain elements or certain frequencies that can't exist in in other realms. I think that, uh, a toxic environment. Like my energ is not going to sustain an intoxic environment. It's just not. It's just not. It's not necessarily even a personal or emotional preference. It's more of like a oh, this doesn't go in there. Like this doesn't go there or I don't exist over there. Like, I don't, you know, it's not. I think I wish that I could be applied to like every space and time, but I think that there are certain drawbacks to being in energy that is applicable to anything and everything. I think that, you know, in the very rare circumstances that an energy like that exists, um it's very magnetizing, it's very, uh enigmatic and it's very charismatic in the way that, like, everybody wants it, everybody wants a piece, everybody wants to be around it, but also for that person, you know, where that energy exists, you know, for that vehicle, I think that it becomes like exhausting to the point that, you know, um, the human of of that, um, you know, the human of that energy is entirely vulnerable all the time. And so those people that are, um designated to do those kinds of jobs, having that high level of power and energy are also, uh, you know, in every sense of the word, um, like exhausted to some effect, um, and I'm exhausted, um, but I think that this last two years has been a case study for all of the like I mean, like she's just horrible things people are doing to each other to try to get ahead, you know, like to try to get a little bit of the pie just to get the tiniest crumbs or to get you know, people are stepping on heads out here. Like people are doing what it takes and they're justifying things that are technically morally, you know. so very morally, uh, corrupt and so so so bad to other people with the justification of like, that's just the way it is. Or you you gotta do what you gotta do and I'm like, yo, dude, but like again, my energy just does not exist in that space for that mindset you know where it's like you know, um because I also believe that like a certain level of justifying, you know, morally uh, you know, morally corrupt behavior eventually just makes it so that you can't get ahead. I I honestly chronically believe that, like if you're constantly fucking other people over just to get to the top, like your top is not going to be consistent with what is actually success and what is actually um freedom, you know, like, you are gonna owe back energy to a certain extent, you know, um, because you stole it in the first place, like, you can't you can't sustain on stolen energy. Like you cannot do it. Like you cannot exist in a place that that was taken from somebody else without something else in turn being taken from you. I honestly truly believed that with every like with every last breath, with every last word, I honestly believe that like that that good overpowers evil. Like, you can't sustain on something that you robbed from somebody, you can't sustain on something that you you know, that that you took, eventually, you know, karmically, um, it comes back too, and so, I don't think energy is any different. I think if you suck the life out of somebody, eventually something' gonna get sucked out of you and, uh, it's one of those things where it's like one step forward, two steps back for people who uh subsist on energy that way. I just I don't know. um, I try more and more to be conscious of my self to point where I realized that um the effect that I have on people could be, you know, long lasting. It's it's something that could be like a ripple effect, and so I'm very careful with my energy in the way that, you know, I if I dole it out, I expect I expect 39%. I don't know why that's the number. 39% to get it back. um, you know, on a certain way. And uh understanding my limits and my like just understanding my ability and my placement. understanding the, you know, the the love you make. yeah, all that. and the love that you make is equal to the love that you take. And so um also, I think that love in itself is probably the most valuable heat source and that it overpowers what is um technically needed in the society of, you know, for survival. I think that love overpowers, you know, whatever material, you know, the material sense of existence is. I think that love overpowers, whatever is morally corrupt, whatever is systematically corrupt. I think that love at the end of the day, like, really does put in its place. um what is supposed to be and what is not supposed to be. And so in because I think like living in this spirit with the understanding that like it took me a really long time. I think I having a a a victim's mentality of like, I must deserve this in some sort of way, but then understanding also like I didn't do anything wrong. Um Sometimes these things just happen and the understanding of why that is is not always attainable. Um, and so to wallow in it and to be like, why, why? You know, like, why? I mean, I think in a from a philosophical standpoint, I do a lot of this because it's like this doesn't necessarily make sense, but it has to it has to be an art artistic way for me to be like, well, it doesn't make sense, but like, you know, now I have ten pages about trying to figure, like, instead of actually just wallowing it and being like, what? Well, now I have ten pages of like this, you know, something that can be considered beautiful. you know, something that can be considered, uh, useful to somebody, maybe not now, but at some point in time, you know, because all of my work is is stored in like this digital time space, kind of like encrypted into history in itself being like a digital marker for, you know, something that very much did exist or did happen. I still believe I still live in the belief that like this, well, it's just like the overall knowing that this part, this faction of history is a very, you know, uh verifiable part of ancient history, you know, to a culture that exists like beyond our time. And so with that understanding that, like it's so crazy, because I do have this overriding kind of factor of, you know, God that's just kind of like, oh, these are ancient times. this is an ancient world and it's hard to like wrap your mind around it because youth, you know, you think of yourself in the present time of like being a, you know, a being of existence in the future. Oh, I watched the jet the Jetsons. Oh, that was so good. I watched uh the Jetsons. which I didn't know is also the Simpsons. and like every animated show that came out on it like a lot, actually. It's a good show. I got I think I gotta watch it again because I was like, oh, this is like ten different shows. It was like ten different shows. um but I watched like the pilot, I think episode of the Jetsons and I was tripping. I I was tripping. um it was just really good. Anyway, um I think what what was I saying? Oh, like this time being like a marker for actual actually being a primitive civilization. Whereas like not necessarily compared to what we know as the primitive civilizations, you know, of human time, like, you think of primitive civilizations of being like the ancient Egyptians or, you know, the Mayans or, uh, you know, the Greeks, uh loved them. I really I I almost even favored them over the Romans. almost, almost, almost, I don't know, I could talk about history and culture forever. cause I'm like, but the other Romans really, like their architecture, but the Greeks more culturally, like artistically, I think where what is the word for them? Uh, the Greeks? What is the word for them? I think there were definitely more, uh yeah, yeah, definitely more artistic philosophical than the Romans, but the Romans had like a lot, like a lot to do with modern society to the point where that's also uh admirable. I do like the Romans. They're just like shitty and violent. They're just shitty and violent anyway. um what was I saying? I don't know. I'm wrapping this up. cause I'm hungry. I don't know about a taco, though. This is technically the start of my day. at midnight o'clock. Um, at midnight o'clock. oh, that's what I was talking about. Markers for ancient civilizations. Oh, yeah, this this time is so so far beyond. But I think the the incredible thing about this time that we're living in now presently, um, is that it is so, like there's so much record of it that it does exist beyond our time for, you know, potentially millions of years and into hire and further civilizations. So I kind of live with that, like, understanding of like this this also and itself being like, a part of the ancient world as far as time is concerned, you know? like, in as much a stipulation of like any apocalyptic or societal, you know, destruction is made, like nothing really sees past, like nothing really sees past the fact that, like, they're so much historical information about our present time in the future that it is consistently creating to an adding to like the what am I trying to say? Oh, something about the multiviverse. Something about the cosmos or something. constantly expanding, because it is, but whatever, I actually just kind of made this as a real time episode to so that I could share this song and then um not really like I don't necessarily have anything for you, anything else for you in this season. um it's there. like, there are six or seven other episodes. There might even be some music. oh, all the freaky Fridays or whatever, mix tapes. Did I even post what up Wednesday? I did I did a freaky Friday on a Wednesday and it was arguably the best. of all the freaky Fridays. I don't know if I posted that already. um I don't know if I posted that already. but it's not. Also, like my podcasting distributor is kind of archaic. So it takes a lot of work just to go check on what's been posted or whatever. um So I'm I'm not going to make any promises and be like, oh, go check if that was posted. And if it is posted, I'll just maybe post it again, cause it's worth it. Um, what up Wednesdays? I did it twice, actually. um because it got difficult to do freaky Fridays. It's still kind of fucking difficult to do it. And, uh, I it pains me to realize, like, how physically affected. I've I have been. um cause it sucks, cause it's not just something that's in my head, it's like ow, like, my body hurts. like, I cannot, you know. I can't withstand a certain frequency or electronic exposure that is negative over this much time. Like, I'm just like broken down right now. Um at least I'm still capable, cause I didn't ever think. I was like, I don't think I'll ever run more than a mile again. Um, I probably should um take the proper steps to make sure that, though, uh, now that I'm running again, I take the proper steps, like, I forgot to stretch, and I forgot to drink water. Stupid. Well, I I just felt so good to run. I love those woodway treadmills so much, so much, it just felt so good that I didn't that I couldn't stop and then when I did, like my body is like, okay, like you're stupid. Like it felt really good, so I'm like, all right, like active recovery. I'm gonna do like two hours on the pelotone and then a walk. um, before I run again. and that's what I'm about to do right now. I love getting to the reunion parts of the bad girls club because as the most fighting and I burn the most calories during the reunions, I just finished to season. I just watched the season for the second time. and uh I have a reunion episode coming up, so I'm a I'm— I don't know. I'm pretty boring person to be quite honest, but here's the song. okay, I'm at an hour yet. Here's the song forgetmenot// and follow through. It's not finished. Like if I could give you a percentage on the— what are you doing? Yo, this dudes are weird all day. I'm sorry. Um. He's so funny. He's so funny. Earlier he like earlier he like sneezed. Earlier he sneezed. But like also farted and this scared himself so bad that I could not contain myself. Because he was like embarrassed. but like, also he sneezed and farted and probably could not. He was like, oh, my God. Like, oh my God. And then, uh, I laughed for like a good five minutes after that. He seemed genuinely embarrassed. I was like, yeah. yeah, that that is shocking that you can manage to do something like that. like being a cat, but, you know, oh, he did. It was good. That's why we have emotional support animals, because I needed that laugh. I don't think I' laughed so hard at anything in a very, very long time, so I'm glad I have my little kitty. my satterat, my Mr. Cat, mush matters anyway. uh, was I wrapping something up? I was.ive meods to follow through. this song that's about to come up, and then I'm maybe I'll maybe I'll if it's not out already. Well, if it is, here it is again, what up Wednesday? I'll go dig it out of the fucking archives. you guys couldn't have that. decent. Um, keep in mind that the CDJs at the radio station, where do Freaky Fridays are also very archaic? Um, I'm not complaining, though. I don't know. I don't know if I got to the episode where I was talking about that. Uh, or maybe I got I got fi I gotta figure it out. um I gotta figure out where these episodes are. There's like six or seven. Should I uh honorable mentions or dishonorable mensions? I feel like it borders on both. because I just figured out what apparently the six seven phenomenon is. And I'm actually worried about suburban children, like, having act like, why are they saying this? Because I looked up I looked up where it came from, it came from this rapper called scrilla dude. not gonna lie. One of my personal favorites, cause I love rap, that is terrible to a certain extent. um and it is, like it's not only it's not only like it's not lyrically terrible. He's actually really good um He's actually really good whatever he's saying. I know what he's saying, which is what's terrifying that, like, apparently suburban upper middle class and upper class children are saying this. six seven thing, because it came from this video by this rapper called Skrilla do doot. Yup. and well, it's culture music, like it's it's trap culture music, it's not necessarily drill, but it's done in the style of drill. um, talking about like the culture the culture the culture um that is not necessarily like great. cause he was talking I was like yo. what the fuck are children saying this for? Um, what the fuck are children exposed to this for? Because there was no, like parental block on it or anything like that. And the dude was talking about like, straight up murderer. He was like, yeah, m, like this though. And I was like, oh no, like I I actually kind of dig his music because it's it's like it's the music that was born of like the Young Thug and the low Wayne and themehesine and it's bad. It's really bad. Like it's really bad. like if your kids are saying six seven, like, the origin of that is not, I'm like,o, shout out sc a d do, because that is facts, but also like, like like kids should not necessarily like, everything he was saying and all of his songs, I was like, that's bad. That's bad that you said that. not that you shouldn't, actually. I feel like there, like art exists as a medium to be able to have this level of freedom of speech, and that's why it exists. But also like, if you understand which I think kids obviously don't if they're just like, oh, six, seven, I'm like, okay, like, but obviously, like, this is where that came from. Like, and this is where that came from, and the dude is talking about some stuff that I'm like what? Like, I'm not confused. I know what he's talking about. But like, children should not necessarily like, even if they don't know what he's talking about, this is not like, this is different from like, when I was like, 10 and it's getting hot in here. So take off all your clothes, like that came out or like to the window to the wall, like this is mild, those things are mild, compared to like, the shit that scrill a do dude. talks about. I'm like, oh, what? What? And apparently we little kids are seeing this and exposed to it, like, they don't necessarily know what it means, but he's like, yo, these are the lyrics to my songs. Listen. I'm like, oh, like. That's troubling. That that exists. That's troubling. truly troubling. I'm I'm not talking shit. I actually really like it, but like parental controls, like, my kids should not be exposed to this, like via the Internet. Like, you should not like, this should be something especially if you live in the subrooms like if you live in a house that has rooms, like if you live in a house that has rooms in an all. like the culture that this is referencing and you know what? The only thing that actually made me look it up was like so many people were saying it in the circuit of television that I watched that I was like, it was bothering me. It was bothering me like Labubu was, but Labubu was far less disturbing, far less. I was like, oh, no. this is not cool. This is not cool, David Letterman. This is not cool, because he was like,Yo, what's up six seven? I'm like, you're 106. I don't know why you're saying this. So I looked it up. So I looked it up, and I was like, oh no, like, okay, like we know it's a cultural fucking phenomenon, but like, do you know why? Do you know why? Like, do you know why? And do you know what this man is talking about? Do you know what this man is saying? Anyway. I'm not I'm actually not gonna say it. Like I'm not gonna say it because I think it it exempt exemplifies that's what I'm trying to say right yeah. I think it exemplifies and represents a part of the culture that is deeply, deeply, deeply, deeply wrong. um in the history of the United States of America. I think it's just bad news. It's just bad news. And it's bad news, like it exists, but the reason why it exists is terrible, like it shouldn't exist is it's terrible. It's bad. It's bad and it's bad that kids are saying this. It's bad anyway. it's really bad. Anyway, I got Peloton time, bad girls' club reunion, some coffee to reheat. Here's this song, um there's no anything else for a while. I gotta make sure that like my uh I got to make sure if I get taken out, it's by like a city bus. And, you know, not just because my insides are uh imploding. um and yeah, my insides are imploding. Uh, gotta take care of number one, which is me. So, that self serving thing I get, but, you know, I'm just not the kind to to step on heads or like, I'm not gonna make it, like, purposely harder for you to do something. Like, I do believe in free will to the point where if you're not hurting anybody else, it's not affecting anybody else's, like vibe, like, do what you want, like, as long as you're not objectively or subjectively hurting anybody. Like, just don't hurt anybody, but besides this, you know, take care of yourself, but it's not, you know. I mean, you're not causing any quantifiable harm. Go ahead and, you know? I, um, but that's it. That's that's it for me. Thank you for listening. Is that it? Yeah, forget me nots. It's not finished. I've got a lot to do. Like, I actually had this is a song that actually has like a list, like a handwritten list on a piece of paper of like do this and do that and do this and do that. But like here's what I have so far just in case, you know, the city buses be getting awful close to the curb sometimes. where I stand, I am yep, they do. anyway. um I said more stories to tell and stuff, but now it's not the time or the place. did I say my thing? Yeah, I say my. Dave you were listening. something, you're listening, see you next time. That's it, yeah. Yeah, I don't have anything else. Thank you for listening. See you next time, bye.

Now, and??? Okay! Just another dime, And just enough to find Before I count them up to dollars— But you're turning into wine. What did you ever want? This is my other world. Go shatter you tantric catwalk elsewhere! Don't you know there is a show to put on? A wool to pull over the eyes of the unknown? Why do you have to groan at the quantifiable harm known but justice undone. No harm, no foul No food, no valid excuse for betraying my sacred dopamine, but hopefully you know only no good But words can come from it, And words that fall on blind eyes have no context at all. {Enter The Multiverse} Uncorrected transcript. [excuse my neighbors in the background they're determined to make my life miserable more than likely in exchange for dollar signs.] Okay, my Wi-Fi is off, my Bluetooth is off. Oh, my laptop is open, my Wi-Fi is on. I can give me a second to remedy that. Hello. Hello. I'm Atticus's tail says hello. What's going on? Oh, I wasn't planning on oh, my WiFi on my computers off. That is good. Uh, I keep all my devices uh, at minimum on off the grid as often as possible. Um, there there actually it's crazy how much of a difference this makes. I gotta pour myself some coffee. it is almost midnight, o'clock. Hello, um, what's up, we're missing talking episodes. Um, we're missing talking episodes from season 12. I can't find anything like past October, and I know it's on one of my hard drives, but all of my hard drives are full, um, I have like something like 10 terabytes altogether of stuff that needs to be like moved around and not all of it. Some of it's like really personal, like not personal, but like sensitive information that I can't necessarily utilize a cloud for. So I am it's taking me some time to organize some stuff. I I try to do between like eight and 12 hours of just organizing on any typical night after my uh exercise or whatever, or between I would say that exercise is definitely like the primary function of like my life. And that's like the priority right now, especially with the things that I've been going through. I think it's really important to keep my physical and mental health as um in in it's not gonna be at its peak, um, because of the noise pollution that I've been dealing with, and it's actually made me really sick over this extended period of two times. um, and I'm trying to um seek treatment for that, but it's a uh it's a long road, I have a long road ahead of me. We could just say that. Um, which is why I am giving you guys, um, some stuff that I've been working on that's not necessarily finished, and I'm actually really like, I'm embarrassed because I don't necessarily um I I actually have a hard rule of not releasing any music until it's absolutely finished. like even if it is a first draft, like it still has to be finished. um, but I actually and I gave you, I think, I think two tracks, which is actually four. um because this upcoming project, it's a concept album called a symposia. um and the concept for it is um a lot. I don't necessarily have to explain right now. Um, but all of the tracks so far on it are double tracks, and so it is typically I've always really loved albums that have that are like gapless. I don't think through my distributor, like I can never technically um, like put out an album that has no um technical stop or start between songs, like they would have to be cut a certain type of way that, like my distributor does it. There's always gonna be a gap between my music, but um all of the tracks are um double tracks, so they're all two tracks in one, um that are kind of along the same theme or idea and um like lead into the next track. I've always loved albums like that. uh, one of my favorite compilation albums, um like just to give you an example, just to throw it out there, is like, the Beatles love album, which is not actually a Beatles album. It's just a, um, it's a compilation of their um songs made for the Cirus Sole show that I think is still playing in Vegas. I don't know if it is it's been playing for like 10 years, and I still haven't seen it. um I really I really want to take mushrooms and go uh see that show. I've wanted to do that since it came out, but my favorite one of my favorite albums in the world is the love album, which is is basically a mash up of like their greatest hits, crafted by, um engineers and people who used to work with the Beatles and stuff for this uh Cir dis soet show um in Vegas that I hope I get to see I hope it's just one of those like long standing like like Siegfried and Roy. I just realized that they were in Vegas for like 40 years, like they were just there, they were just a stable, so hopefully that show is um kind of like that and one day I'll get the, uh one day I'll get the opportunity to see it. Like my my bucket list, like destination, like vacation at one point was to go see the Beatles love on like an EDC week. um that's still something that I want to do. I promise myself I wouldn't go to EDC unless I like ever got booked there. Um, and I think this year is like 30 years or something of EDC, and so they um they sold out in like five minutes. um so it's it's not it's not something I'd consider doing by myself anyway, unless I was gonna go with my best friend, and um and I was like I was talking to my best friend and I was like, oh, maybe I should check on, like the early bird tickets for ADC, and they were like, they was sold out, and was this celebrating 30 years, and I'm like, okay, well, I guess I should uh work on getting a booking agent, but my music is not my music is kind of turned into like a passion project. um, since everything that I've been going through over the last couple of years kind of just like took me off my path in that sort of way and DJing, I kind of wanna preserve it as like, I really love being a DJ. I really love producing music and because it's so consumer, there's a bunch of people in the industry that are not necessarily like music oriented or love oriented, and it's just like a whole different vibration from like the peace and the love and the unity respect of that. Like I like the scene for. I really want to check out, like as far as a festival goer is concerned, I really wanna check out some of these new festivals that are popping up that are doing like no cell phones. I kind of wanna check those out, cause I feel like the quality of of the experience has been preserved or will have been preserved in in certain spaces like that, um, but anyway, I'm uh I have been physically ill for like a few months now. um, and so the best that I can do for you guys my audience just because I'm not sure if I will get symposium out this year in which case it will come out next year. um, and then I think this track, I'm not sure, this track is definitely like a track that was in my mind. um implementing all of the like sound design stuff that I'm doing for symposium and is also a double track. um it's called Forget me nots. uh and then the second track is followed through. uh,get me nots/follow through. I think it's like an eight or nine. um minute track or whatever. It's not finished. Um, actually, the only finished track that you guys have heard, and even this even bitter butter and southwest of your scars is like a double track that is finished, that is on symposium, but it's still the version one, like it's not um I haven't done like any of the final mastering or any of the things that I do in the process of getting ready for a a release. I do have like a a like an implemented ritual structure of doing things like that, even for projects that seem like mindless, or, you know, things that are seem seemingly just like thrown together, like chasing dragons, was kind of like not necessarily even a concept until the three tracks were like sandwiched together, and I was like, oh, okay, like, this does tell a story and and they were all created in a certain way so that they'd go together. I think I fixed that. um, because, um, chasing dragons, the EP was for some reason, when chasing dragons got released to, like all the major platforms, it had chasing dragons was the first and the last track, and then dishes and the sink was just in the middle, which was weird. um so the third track on chasing dragons is actually immortalist and I got that all fixed. and I also got the regular like the normal version of the songightfall is out on the platforms now. Those were two er errors um that I needed to fix that I finally did. um but I'm slower to do music things now because like I said, my health is the priority. So it's like, yo, if it comes down to like getting a good meal in or like some good exercise or like right now I'm doing active recovery because I'm dumb. I went from like not really running anymore and only walking for an hour every day on the treadmill and doing like an hour between one and two hours on the pelotone, a day which is technically still three hours of work, um, but then I went back into heavy training the way that I preferred to do like I prefer to be at the gym between two and three hours every day. That is my ideal. That is where my body feels comfortable, um and flexible and like happy. Um, and if I can do that in the very beginning, like to start my day, cause I don't necessarily have 24 hour, like days anymore. um like what's technically the end of my day is oftentimes the very beginning of other people's days, and so I'm kind of just on on night, like, routine because it is like, I'm I'm basically just like protecting myself from the uh, you know, like my my nervous system can't take any further damage. Like, I do have really pronounced synesthesia and, um, I wasn't necessarily like planning to be exposed to extreme like noise pollution for an extended period of time without having the financial security or stability to escape from it, cause honestly, if I could have moved, I would have moved or if I could have just left, I would have just left, um, but I obviously wasn't in a situation that I could, and so I became very vulnerable um, to this type of attack, which I learned was actually very common. It's not something that is just like, oh, you know, um, this is just something that I'm going through. It's actually a very common for people of color to be, um vulnerable to this kind of disease that comes from um an implementation of using sound as a weapon. And I mean, like the irony is is that I was already kind of studying synesthetics and the way that, you know, as a culture or the way that in as as far as like mass consumerism is concerned, that's why people pay so much for a, you know, festiv for the festival experiences because sound can be a very much uh manipulated to be a physical thing. It's not, you know, it's not invisible. And so the fact that those same kind of um those that same kind of engineering can be implemented also in a negative way to have a negative effect. Like, you don't have to punch somebody in the face, like, you can just back up your exhaust, your engine exhaust, and, you know, fire at point blank to somebody that is, you know, caught off guard. and in that way, um sound can be used as a weapon, it uses the same dynamics, the same kind of dynamics as, you know, the reason why we go in the th you know, in flocks by the thousands and the millions to these festivals to feel the vibrations that that are on the opposite end of the same spectrum, the healing vibrations of, you know, certain things. and so I've been doing my best to try and, you know, maintain a certain level of health through, you know, using, um, you know, certain frequencies to block out. But when it's your physical person is in a space that's being manipulated to be on a certain frequency, um, uh, the exposure to this negative frequency that is unnatural to your body over a period of time. um, you begin to get very, very sick and that's what's happened to me. And so I'm trying my best to like keep my head above water and, you know, stay afloat. Um, but I didn't expect it especially after, you know, a period of like two or three years before that, where I was just like on the go all the time. Um, and, you know, not necessarily having like a a suitable foundational stability or a place to call home and then going straight into something else that was like more traumatic and more violent than, um then I expected, and so I've been trying to remedy that. um, the best that I can and because I'm putting my mental health and my physical health first, I'm not necessarily like, I it was weird. I was kind of in like a meditative space and I had, you know, like this this kind of spirit come over me that was like music, you know, music is gonna be there forever. like, as long as you're as long as you exist, you know, whether it's in like a physical realm or like an infinite realm or whatever, like as long as you exist, there's always gonna be music. and that was kind of like the sign that like, K, as much as I do like having a streak of, you know, like being an Ableton every day for several hours a day. um, the way that I am using these techniques that I'm applying in symposium and as seen on TV, which reminded up being a double album, because I actually have, um, like several, um, tracks that are like honestly on TV, I've been working on since, like, 2023., like, early 2023. Um, and so, the things that I've like collected, it's kind of interesting because my evolution as an artist or like my technique as a producer will be, um represented here in this project, which I hope comes out next year, but I can't say for sure, cause it's probably the it's definitely the biggest, most um important album I've ever worked on and I I put a lot of care and thought into those as seen on TV tracks because it does um like creatively, I guess, run alongside this series into the multiverse and all the series within the festival project, uh Ascension Death Wish, legends, um the legend of uh, the secret life and the sweet life of sunny Blue, just to name a few, there are I keep trying to make like a list of all of the shows within the festival project, but then I'm like, oh, like there are so many that it would it just falls apart. And so I mean like I'm getting a little bit more organized with the with the actual structure of, like, the television and movie, like, script part of the project. um, while I'm cleaning out my hard drives, but having to organize everything so that it's, you know, so that I can go to a certain hard drive and be like, okay, well, this is um, you know, this is this season to this season. I'm still archiving episodes from, you know, 2021 and and because a lot of those statistics can't be like once I delete an episode from the podcast, it goes away and all the all the statistical information about the number of downloads,, like all of its information, all of its metadata goes away. and that's very important for what I'm going through in my personal life right now in order to protect myself for those things to be taken down, but also for it to be archived in a way that I can reference as a creator like, okay, this is this day that this was published with this, that like, because it's it's a time travel concept that is multifaceted, and it is like based in this multiperceptory m multiperceptory multiimensional concept of technically technically infinite time and space, like it has to be organized in such a way that, like, all of the series and all of their all of the ways that they're connected to any particular parallels have to be, you know, they have to be organized and documented so that because I'm the more that I'm looking at it, the more it makes sense. I'll be like, oh, like, I thought this was just like nonsense or whatever, but when I'm putting it into like an organized space, um, and to me, that's like the god part about it is that like, oh, like, um like, I' I'll be looking at the writing and noticing how it takes like particular shapes or how the shapes will cut is sometimes like make pictures, like sometimes when you're looking at the clouds and you see, you know, shapes and the clouds. sometimes the riding for this project is like that, which is kind of incredible to me.c it's not something that I'm doing um, intentionally, it's kind of just something that's happening. I'm writing in a stream of consciousness that's also, you know, like artistic, creative in a way, that kind of has this, like, sense of divinity to it that I'm not necessarily, like, consciously doing. Um, so everything has to be organized in such a way that like it is gonna take time, um, and because it takes time and a lot of the other things that I did not foresee happening or also taking a lot of my time, like a lot of my my time and energy to document like how sick I've been getting a lot of time and energy has been focused on just like, doing the research on, you know, like crazy crazy shit that I never really took interest in, um, but could be applied here. um, could be applied to this situation and and kind of just finally being able to have a piece of mind to give myself the benefit of the doubt that, like, it wasn't in my head. like, I just had to be uh, I just had to be pushed to the point that I could understand, you know, that this um, sometimes very silent type of, um, you know, warfare is is like a documented not even necessarily historically, but like presently and present day. um, they're just I don't think haven't been enough survivors of this kind of thing, um, that it could be, um that it could be notably researched, like the amount of reports, but, you know, it's it's not it's not by choice, like it is taking up a lot of my time and I wish I was the kind of person that could just ignore it. Um, but I'm getting very physically ill. Um, so I can't, like, I can't ignore the fact that, like, you know, I'm running on zero pretty much all the time, and that my my patterns of speech have changed in my, you know, my thoughts have been intercepted and my, you know, like, because physical and mental health is such a priority to me, the fact that those things have been the primary uh, source of degradation has has affected me in such a way that it's not, I mean, like, it's less emotional than it is the logical answer to, you know, like if you have a cold, you take cold medicine or if you have the flu, you take, you know, it's it's like, well, remedying something that is a fi physical illness, you know. um, removing the cancer from the body, uh, you know, in such a way that it doesn't come back is kind of my main primary concern in this way. Um, so I am am especially because I can't but the talking episodes are actually more popular this season than any other season. and I can't find like six or seven of them, because I I don't know, I was just switching out all my, you know, uh my stuff so quickly and pulling things out of the cloud that it, you know, got saved under drive zip eight, seven six nine, you know, like. It's it's just a mess of of terabytes and tabyrites of creative work, um, and, you know, other things that I've had to dedicate my time to, which is not necessarily fair, but, you know what they say is life is not fair. Um, so, you know, life hasn't been fair, but I have, you know, been blessed in such a way that, like I I I've at least been able to um creatively channel some of the some of the energy and some of the time that I have left over that is technically mine. while in the sense that I've had a lot of my time and energy just stolen in siphoned, um, you know, I have been able to kind of forge a medium through fighting this that allowed me to, you know, start doing art along the lines of, um more more the way that I want my music to to think and feel. And so I'm I'm still just working from a little tiny MacBook air. um, so my, you know, um, my projects get like overwhelmed really quickly. I can't necessarily implement all of my um my plugins or all of the tools that I like to use at once, and so everything is kind of segment segmented in the way that I'm working. um and like, yeah, my projects get overloaded very quickly. um so the tracks that I'm giving you are not finished, but they're more um I would say like they're more, like colored, they're more like filled out. It's not necessarily abstract in the way that some of my stuff is like very like, you know, like drag and drop and cut and go, well, I do a lot of like, even in my even in my like my cut and dry stuff, I do a lot of sample manipulation. I very rarely will keep a sample in the way that it is without doing something to it, you know, like, I don't do dragon drop, um, unless I'm planning on just, like, you know, giving a beat to a rapper a artist for free. like, sometimes I'll just be like, okay, for the next 15 minutes, just do, like, something, you know, like a two or three minute, like dragon drop or whatever. But those those are not necessarily tracks that I A share here or B like plan on doing anything with because the world of sampling has gotten to the point where it's like, yo, you gotta have some creativity, like you can't just open up a sample pack and drag it and drop it into place, because then you have eight or nine songs that sound exactly the same. Eight or nine songs that are the same because basically you're just putting together a, you know, you're putting together stems from a track that was already created, you know, by somebody that's trying to sell you something, so um, you know, I I take a little bit more creative uh integrity in the stuff that I do mean seriously. Um, a lot of it lately hasn't been serious, but I I actually did want to take an hour to talk about this not this track in particular, just talk about why I'm doing this because it was something that it was like, oh, I feel like this project is a little bit more special or is a little bit more like technical than some of the other work that I've shared here on this podcast or work that I've put out before and so I kind of wanted to keep it to myself um, but then I've kind of had a couple, like, you know, like heart shattering experiences that make me realize, like, you don't know. like, you don't really know what's gonna happen and life is, um, sometimes very cruel and sometimes life is, you know, it just takes turns that are not necessarily. um you know, like you don't you don't ever know. And my mindset has not necessarily been that negative. It's like, oh, everything, you know, there's a there's a reason for everything, and blah, blah, blah, and I still do believe that, but like, you know, two years of constant, like, torture and stress to the point where I don't necessarily have a medium for support or, you know, um, like, I don't necessarily have the foundation of community. um, being in a place that is not my home and coming from a family that's very, very small and doesn't necessarily have, you know, well, like, I don't have what some people have, I don't have a large network of family and friends and the kind of family and friends that you create for yourself in the business are not necessarily, um, you know, like people can't necessarily be trusted to have your best interests. Um, especially especially if you are coming from like a a margin for success that, you know, is documented, like you've done well, you can't necessarily still believe that, like, everyone in your immediate circle has the best interest for you, because it is in human nature that everybody has, you know, themselves as the primary interest, and so um, me being like a a solidly um you know, like self sufficient. I won't say independent person. um, driving towards independence or whatever. um, but being a person that spends a lot of time in solitude and with enough respect, like enough self-respect to understand what my when my spiritual and my personal boundaries are being pushed even even in a person you know, professional setting. um like I took today for active recovery because I'm dumb and I went straight back into training as if I'd never really stopped. like it okay, like I'm on the Peloton seven days a week and I have a treadmill that I walk on in for an hour a day, you know, five to six days a week, but it's not the same as like being in the gym and lifting in stri strength training and and um active recovery um but I was like, okay, if I was running like a Madonna or whatever, you know, for this amount of time, then I should be able to do that. I should be able to do that. No, I didn't run a Madonna, but I ran like a 3K and then a little bit. and I like, my body was like, yeah, this is good, but then I had, like the rest of the day and I did not properly hydrate, and I got, like even more sick. and so I'm like, oh, fuck. Like, I really got like I really got a prioritize, like, my physical health, because if I keep letting myself get pushed, you know, like over the summer, before requisite when I was just like, oh, you know, like, I'm just gonna record. I'm gonna go to Manhattan 20 fucking days in a row and not take a day off and I'm also gonna train, you know, and I'm also gonna do this, like the like, I'm maximized my potential for burnout, which also left me per like, personally vulnerable. to the, like, professional sabotage and, like, weird, underhanded, like, underbelly shit that, like people in the DJ circuit are doing because it's so hard to actually break through., from the level of like consumer professionalism right now. So people are doing like a lot of nasty things to try to get that main stage spot and I wasn't like in my head, I'm still very much like a Disney kid, like, I'm still like, I don't necessarily well, I mean, like Disney to teach us like, there's always gonna be a villain, but like, a society kind of undoes that teaching and is like, but that's just in movies and that's just in your head, but there's no like to me, I there is just this weird misst up between real life and what is told that like, okay, like anything that exists that is like in a certain field of negativity is just in your head. but, like, evil is it like a documented source of the opposite of good. since the beginning of time, and I just don't understand in how in a society we can philosophically and psychologically embrace therapy, however, when it when it comes to, like, real lived experiences, when you're dealing with something that is not necessarily, uh, like a normal part of societal living, like that stuff only happens in movies. I'm like, but it does happen. Sometimes you just have to, you know, like being having I've I've never really been such a socially dependent creature. like, a lot of people have to have some kind of validation. That's why social media is like ruling our society right now. is because people have to have the validation or the likes of whatever they're doing is like cool with the rest of the group. and to me, that this is dangerous group think. like, if you're all thinking the same way, then there's something being missed. There's always something being missed, you know, if you're all on the same frequency or the same form of thought, you know. And so, I've always been like a big, you know, maybe it's just because I don't have any siblings. I've been like a big believer in embracing, um, independent thought, like, okay, if everybody else is thinking one way, then what is the opposite of what everybody else is thinking and not necessarily alluding to the fact that the opposite might be the right thing, but anything between whatever the group think and the opposite is, is also like valid, could be valid, you know, it's not necessarily the opposite of what everybody's thinking, but it's somewhere along the spectrum of maybe that or maybe the opposite, like it could be anything else in between. And so I think I'm the kind of person or the kind of thinker that's motivated by the the spectrum, you know, the spectrum, uh process, anything in between, like not necessarily that, not necessarily the opposite of that, but like what other possibilities, you know? um, could be validated or verified through thinking outside of the box or outside of a you know, being forced to the point of conformity that, like, everything sounds the same and everything looks the same and everything has like a way. That's not necessarily wrong. um, but also not necessarily the only way or right. um, so that I' of been uh what what did I get on that round about? I don't know. I've just been playing with like a lot of different concepts, like not necessarily trying to sound like anything. or anyone, and also not necessarily having the opportunity or environmental expression, like the space to be able to sound like myself. Like I still don't artistically or musically think that I sound like myself. um, and that they are elements of myself there, but it's something that's kind of, um, in its, you know, convex form of being this thing that is potential, but not necessarily fully realized or realizable yet. Like, I haven't had I haven't had peace and I haven't had like full p I haven't had peak health in a long time, or a safe environment in a very long time. and I think that the disallowance of comfort, not necessarily the safity of um of complatancy, you know, or or being comfortable to a point that it's it becomes dangerous, um, but just being able to kind of be in a life that is not necessarily like violent or terrible all the time. I think removing these barriers has not necessarily been a foreseeable reality for nearly a decade and while some artists technically thrive in what is, you know, what is this, you know, tragedy and darkness? It's there's only so much of a certain space that my creative ingenuity can take up and not void. And so, understanding that this time is kind of transitional in the sense that eventually it has to in no matter what direction break free from its current state of, you know, entrapment and its current state of imprisonment. um and so in my artistry and not will change, but I don't think I don't think it's necessarily going to be like fully realized until I have a a a point that I'm in an environment that I can breathe and be and think clearly without the force of control or being subjugated to, you know, a certain level of violence that's not necessarily always physical, but is certainly not, um, you know, without it's notable, um, impact on my physical health, my physical and mental health. So that being said, um, this track, um, this track is somewhere between symposium and, um, as seen on TV, I think I began writing it before the concept for symposium was fully formed. and, um, I think it was like the first of its little group of double tracks and I didn't necessarily mean, like, for the story, cause it, you know, ideally, like a song is like five minutes or less or whatever. um five minutes or less or whatever, but I've again, not been, uh, trying to conform to what is supposed to be this, or what is supposed to be that, and, um I don't know. I I began writing it in with the mindset and the technicality of symposium, but also as I listen back to it, um, I'm also using elements that have been implementing for the last few years into as seen on TV. And so there's some like to me, it's very beautiful. Again, what what is more important or more, you know, like wh what is more palatable for my audience is always differed like my favorite tr tracks are not your guys's favorite tracks from what I'm looking at for for the numbers, you know, my favorite episodes of me talking are not your favorite episodes for me talking. So, I mean, like they're exists here, this obvious, like, it's weird because a lot of artists can be applied to their fans and to their listeners. It's like the the listeners are being projective of like they see themselves in their favorite artists, or they see themselves reflected back through an artist that they, you know, like Taylor Swift, like, all her fans are Taylor Swift and like, most artists are that way that, you know, they're reflective of the people that they look like and have the same experience of and that's how, you know, um, that's how mass that's how mass media works. It's reflected, you know, through the medium of sorts, you know, um it as a as a concept that is shared amongst all all of those, you know, people. um, but I'm looking at my numbers and I'm realizing that, like, oh, there there's like a distinctly different flavor from the way that, like, my perception of what is my best work is and what my audience thinks is the best or, you know, the like I look a lot at the numbers not as they happen, but like over time, whereas I'll be in hiatus for a certain amount of months and then I'll come back. and see what the numbers are reflecting in in what is more, you know, palatable for my audience, like what my audience is is actually agreeing with more is like my better work and it's always not it's not necessarily again, it's not necessarily opposite. but it's not um, you know, it's not always what I expect to be. So this to me, I like um, but it doesn't necessarily like that you, whoever you are as an audience is gonna agree. Um This is actually the least completed track. um I feel like I'm showing you yeah, like I'm showing you my my uh it just it's naked cause it's very much not done. This is probably the most incomplete thing that I've ever, like, put out for anybody else to listen to. Um, but just being audit honest as like a person, not like as a entertainer, cause I don't necessarily see myself as that anymore after these couple years. Um, but being honest, like as a human being, as like a person, um, I've had some times that feel as though are, you know, an indication of not having a very prolonged experience in this sort of way. And I don't, like, I don't wanna put a trigger warning on anything. And I don't wanna, you know, like I I also don't want to insinuate things that are not there. Um, but a lot of the time, that is just to say that I don't feel safe, um, that I don't feel, um safe or secure, um, and that there's not necessarily a like sh it's just New York City. There's no level of like autho like a there is no necessary authority complex that has any sort of like, ability to protect you, you know, from uh certain experiences that are not necessarily um, you know, there's there's no level of protection from from, you know, there there are more heavily funded organizations that are like banks and investments or are more funded than the police. So when you're telling the police, like, hey, I'm being, you know, stalked or harassed and like, there's a pattern and like, here's the evidence and they won't even look at your evidence. Um, even though technically by the law, like it is, you know, documented uh, verifiable, like verifiable, like, no, there's none in my head. Like, I have like the videos, I have pictures, I have audio recordings of like this is happening to me, and they won't even look at it, um, not necessarily because they don't want to, but maybe because they've been trained to look in the other way. Um, and then, you know, just the cultural disadvantage of like, youre snitch. I'm like, I'm also within inches of my life sometimes. and nobody's helping me. Um, and it's not necessarily a mental condition. I think that more now than ever, I would be like readily willing to admit like, oh yeah, like, I should just take the meds, but I'm like, this is I'm not hallucinating this. I'm not gonna take some kind of fucking pill for some kind of medication for something that's like, I'm experiencing this, and not only am I experiencing this with like my eyes, my nose, my ears, like, I'm now videotaping 100% of my life everywhere I go. If I walk out the door, I'm recording, like, that's how many times I've been stalked or followed. Like, if I walk outside of my apartment, like I'm I'm videotaping it, because if I don't, if something happens, then it's literally their word against mine. and the police is, like, literal their whole thing is like, if we didn't see it, it didn't happen. Like, you can get you can get, like beaten within an inch of your life and the police can show up and you can tell them and they can see you like bleeding from the face or whatever, and be like, that guy did it, but the police will straight up tell you. the police will straight up tell you like if we didn't see it, it didn't happen, like we can write the report, but like we like they will not investigate. Period. They will not investigate. And so understanding that, like that opens the, you know, the possibility of like way, way more heinous crimes, you know, being able to be, um, played out without, you know, without any possibility of you having help for that, as, you know, is like dangerous to me, and a lot of the time I feel like I'm in danger, um, to me, and so, my priority is not sitting down in Ableton and and you know, getting these cues just right, like, especially with this this track. um, like it's so, so far from complete, but when I hear it, it still sounds it sounds decent enough that, like, I'll give it to you guys just in case, like like the least sometimes that I feel is gonna happen is that I just get hit by a bus. uh, which does happen almost any time I go outside. It's like, I will not get a bicycle. I won't because I'm like, that's like the easiest way to ensure that I will get hit by something. I'll get hit by something. um I will get hit by something, so I don't um I don't, you know. I'm just trying to, uh, get along and protect myself and away that, you know, maybe possibly enables me to, like, disappear. I don't necessarily need to be anybody. I stopped fighting for that main stage spot a long time ago, cause I I see that it's not about like it can't necessarily be about the love when it's about the money. and I have so, so much love. like for the music, um, and for what used to be the scene. I mean, the scene's always been kind of dirty. You pick up any book about DJ culture, about festival culture, you know, about music in the in the sense that it's been meant in the rave world has always had like a CD side to it. um because it was previously a counterculture, you know, that became mainstream and it still definitely has its like flavor, it definitely has its like, you know it's flavors to it, which, you know, is is a magnetism or like a draw, that's like, oh, there is this darkness that exists, but like, at the core of it is the frequency, you know? And I think that if there was ever going to be like a place for like a placeholder for success for me and the industry, it would be somewhere in the future when it can be a more decisive. No, what am I trying to say? Oh, I don't know. I think that money really fucks things up sometimes, and because of the amount of inequality in the world and the fact that the the world has become such a competitive space, um, that there're actually less places for opportunity for artists, even though it seems like there should be more. um I think until it's like about wellness, yeah, I think in until music can be until we can create like spaces where wellness is like at the center of these, you know, gatherings, then I don't think it's necessarily going to be like a safe place. Um for anybody, but let alone for me, because I'm very much like a fragile person when it comes down to, um, like per like the protection of my spirit and the protection of my aura, I don't necessarily want to be in a place of uh tragedy or a place of defense all the time. I I wanna go outside and and be in defense mode 100% of the time. I am right now, so um, like anything I I I kind of take it with a grain of salt in the way that like anything I say can and will be used against me. And so I don't say so much. I I don't say so much, and I want to be sure to take care of my art in a way that it doesn't is not, um, you know, so that it doesn't necessarily exist in a place of toxicity or that it's not coming from. Like, I won't sit down and Ableton if I feel a certain way. It's not just me being lazy. Like it's if I have like a certain vibration that's incurable, like it's not uh it doesn't make sense for me to, like, you know, sit down and work on a track. So this this track, uh, forget me nots and follow through. um, I think it is the first track and symposium. I don't know, because when I listen back to it, I also hear um when I listen back to it, I also hear as seen on TV, like a lot. um like a lot. And so it's kind of interesting to see those two kind of elements of my artistic personality combined, because I think the tracks that I've shared with you that are from symposium or different in the way that they're um made only one way, but this one is definitely implementing um techniques from two projects. Um, so the what are the two other ones? I think it's like talked to me about it. Is that oneosium? I think so. and bitter butter and southwest of your scars. Ah, those are all from this project, but then I I look at this one, which is technically the first of the bunch and it's so not done. that I'm like, don't put it out until it's done. and I'm like, well, and might not ever be done with the shit that's happening is kind of scary. Like, it's I might I may not ever be able to get back to a place where this is possible because of the things that are continually happening uh, to me. Um, I I don't know what the source of evil is. Like, I really don't, like I am very much a spiritual person and I do have like the tendency to believe that like no matter what God has my back so if I'm removed from one situation or existence into another, it is for the protection of that aura, for the protection of that frequency, for the protection of, you know, keeping my, you know, um my source intact, like there's, you know, certain elements or certain frequencies that can't exist in in other realms. I think that, uh, a toxic environment. Like my energ is not going to sustain an intoxic environment. It's just not. It's just not. It's not necessarily even a personal or emotional preference. It's more of like a oh, this doesn't go in there. Like this doesn't go there or I don't exist over there. Like, I don't, you know, it's not. I think I wish that I could be applied to like every space and time, but I think that there are certain drawbacks to being in energy that is applicable to anything and everything. I think that, you know, in the very rare circumstances that an energy like that exists, um it's very magnetizing, it's very, uh enigmatic and it's very charismatic in the way that, like, everybody wants it, everybody wants a piece, everybody wants to be around it, but also for that person, you know, where that energy exists, you know, for that vehicle, I think that it becomes like exhausting to the point that, you know, um, the human of of that, um, you know, the human of that energy is entirely vulnerable all the time. And so those people that are, um designated to do those kinds of jobs, having that high level of power and energy are also, uh, you know, in every sense of the word, um, like exhausted to some effect, um, and I'm exhausted, um, but I think that this last two years has been a case study for all of the like I mean, like she's just horrible things people are doing to each other to try to get ahead, you know, like to try to get a little bit of the pie just to get the tiniest crumbs or to get you know, people are stepping on heads out here. Like people are doing what it takes and they're justifying things that are technically morally, you know. so very morally, uh, corrupt and so so so bad to other people with the justification of like, that's just the way it is. Or you you gotta do what you gotta do and I'm like, yo, dude, but like again, my energy just does not exist in that space for that mindset you know where it's like you know, um because I also believe that like a certain level of justifying, you know, morally uh, you know, morally corrupt behavior eventually just makes it so that you can't get ahead. I I honestly chronically believe that, like if you're constantly fucking other people over just to get to the top, like your top is not going to be consistent with what is actually success and what is actually um freedom, you know, like, you are gonna owe back energy to a certain extent, you know, um, because you stole it in the first place, like, you can't you can't sustain on stolen energy. Like you cannot do it. Like you cannot exist in a place that that was taken from somebody else without something else in turn being taken from you. I honestly truly believed that with every like with every last breath, with every last word, I honestly believe that like that that good overpowers evil. Like, you can't sustain on something that you robbed from somebody, you can't sustain on something that you you know, that that you took, eventually, you know, karmically, um, it comes back too, and so, I don't think energy is any different. I think if you suck the life out of somebody, eventually something' gonna get sucked out of you and, uh, it's one of those things where it's like one step forward, two steps back for people who uh subsist on energy that way. I just I don't know. um, I try more and more to be conscious of my self to point where I realized that um the effect that I have on people could be, you know, long lasting. It's it's something that could be like a ripple effect, and so I'm very careful with my energy in the way that, you know, I if I dole it out, I expect I expect 39%. I don't know why that's the number. 39% to get it back. um, you know, on a certain way. And uh understanding my limits and my like just understanding my ability and my placement. understanding the, you know, the the love you make. yeah, all that. and the love that you make is equal to the love that you take. And so um also, I think that love in itself is probably the most valuable heat source and that it overpowers what is um technically needed in the society of, you know, for survival. I think that love overpowers, you know, whatever material, you know, the material sense of existence is. I think that love overpowers, whatever is morally corrupt, whatever is systematically corrupt. I think that love at the end of the day, like, really does put in its place. um what is supposed to be and what is not supposed to be. And so in because I think like living in this spirit with the understanding that like it took me a really long time. I think I having a a a victim's mentality of like, I must deserve this in some sort of way, but then understanding also like I didn't do anything wrong. Um Sometimes these things just happen and the understanding of why that is is not always attainable. Um, and so to wallow in it and to be like, why, why? You know, like, why? I mean, I think in a from a philosophical standpoint, I do a lot of this because it's like this doesn't necessarily make sense, but it has to it has to be an art artistic way for me to be like, well, it doesn't make sense, but like, you know, now I have ten pages about trying to figure, like, instead of actually just wallowing it and being like, what? Well, now I have ten pages of like this, you know, something that can be considered beautiful. you know, something that can be considered, uh, useful to somebody, maybe not now, but at some point in time, you know, because all of my work is is stored in like this digital time space, kind of like encrypted into history in itself being like a digital marker for, you know, something that very much did exist or did happen. I still believe I still live in the belief that like this, well, it's just like the overall knowing that this part, this faction of history is a very, you know, uh verifiable part of ancient history, you know, to a culture that exists like beyond our time. And so with that understanding that, like it's so crazy, because I do have this overriding kind of factor of, you know, God that's just kind of like, oh, these are ancient times. this is an ancient world and it's hard to like wrap your mind around it because youth, you know, you think of yourself in the present time of like being a, you know, a being of existence in the future. Oh, I watched the jet the Jetsons. Oh, that was so good. I watched uh the Jetsons. which I didn't know is also the Simpsons. and like every animated show that came out on it like a lot, actually. It's a good show. I got I think I gotta watch it again because I was like, oh, this is like ten different shows. It was like ten different shows. um but I watched like the pilot, I think episode of the Jetsons and I was tripping. I I was tripping. um it was just really good. Anyway, um I think what what was I saying? Oh, like this time being like a marker for actual actually being a primitive civilization. Whereas like not necessarily compared to what we know as the primitive civilizations, you know, of human time, like, you think of primitive civilizations of being like the ancient Egyptians or, you know, the Mayans or, uh, you know, the Greeks, uh loved them. I really I I almost even favored them over the Romans. almost, almost, almost, I don't know, I could talk about history and culture forever. cause I'm like, but the other Romans really, like their architecture, but the Greeks more culturally, like artistically, I think where what is the word for them? Uh, the Greeks? What is the word for them? I think there were definitely more, uh yeah, yeah, definitely more artistic philosophical than the Romans, but the Romans had like a lot, like a lot to do with modern society to the point where that's also uh admirable. I do like the Romans. They're just like shitty and violent. They're just shitty and violent anyway. um what was I saying? I don't know. I'm wrapping this up. cause I'm hungry. I don't know about a taco, though. This is technically the start of my day. at midnight o'clock. Um, at midnight o'clock. oh, that's what I was talking about. Markers for ancient civilizations. Oh, yeah, this this time is so so far beyond. But I think the the incredible thing about this time that we're living in now presently, um, is that it is so, like there's so much record of it that it does exist beyond our time for, you know, potentially millions of years and into hire and further civilizations. So I kind of live with that, like, understanding of like this this also and itself being like, a part of the ancient world as far as time is concerned, you know? like, in as much a stipulation of like any apocalyptic or societal, you know, destruction is made, like nothing really sees past, like nothing really sees past the fact that, like, they're so much historical information about our present time in the future that it is consistently creating to an adding to like the what am I trying to say? Oh, something about the multiviverse. Something about the cosmos or something. constantly expanding, because it is, but whatever, I actually just kind of made this as a real time episode to so that I could share this song and then um not really like I don't necessarily have anything for you, anything else for you in this season. um it's there. like, there are six or seven other episodes. There might even be some music. oh, all the freaky Fridays or whatever, mix tapes. Did I even post what up Wednesday? I did I did a freaky Friday on a Wednesday and it was arguably the best. of all the freaky Fridays. I don't know if I posted that already. um I don't know if I posted that already. but it's not. Also, like my podcasting distributor is kind of archaic. So it takes a lot of work just to go check on what's been posted or whatever. um So I'm I'm not going to make any promises and be like, oh, go check if that was posted. And if it is posted, I'll just maybe post it again, cause it's worth it. Um, what up Wednesdays? I did it twice, actually. um because it got difficult to do freaky Fridays. It's still kind of fucking difficult to do it. And, uh, I it pains me to realize, like, how physically affected. I've I have been. um cause it sucks, cause it's not just something that's in my head, it's like ow, like, my body hurts. like, I cannot, you know. I can't withstand a certain frequency or electronic exposure that is negative over this much time. Like, I'm just like broken down right now. Um at least I'm still capable, cause I didn't ever think. I was like, I don't think I'll ever run more than a mile again. Um, I probably should um take the proper steps to make sure that, though, uh, now that I'm running again, I take the proper steps, like, I forgot to stretch, and I forgot to drink water. Stupid. Well, I I just felt so good to run. I love those woodway treadmills so much, so much, it just felt so good that I didn't that I couldn't stop and then when I did, like my body is like, okay, like you're stupid. Like it felt really good, so I'm like, all right, like active recovery. I'm gonna do like two hours on the pelotone and then a walk. um, before I run again. and that's what I'm about to do right now. I love getting to the reunion parts of the bad girls club because as the most fighting and I burn the most calories during the reunions, I just finished to season. I just watched the season for the second time. and uh I have a reunion episode coming up, so I'm a I'm— I don't know. I'm pretty boring person to be quite honest, but here's the song. okay, I'm at an hour yet. Here's the song forgetmenot// and follow through. It's not finished. Like if I could give you a percentage on the— what are you doing? Yo, this dudes are weird all day. I'm sorry. Um. He's so funny. He's so funny. Earlier he like earlier he like sneezed. Earlier he sneezed. But like also farted and this scared himself so bad that I could not contain myself. Because he was like embarrassed. but like, also he sneezed and farted and probably could not. He was like, oh, my God. Like, oh my God. And then, uh, I laughed for like a good five minutes after that. He seemed genuinely embarrassed. I was like, yeah. yeah, that that is shocking that you can manage to do something like that. like being a cat, but, you know, oh, he did. It was good. That's why we have emotional support animals, because I needed that laugh. I don't think I' laughed so hard at anything in a very, very long time, so I'm glad I have my little kitty. my satterat, my Mr. Cat, mush matters anyway. uh, was I wrapping something up? I was.ive meods to follow through. this song that's about to come up, and then I'm maybe I'll maybe I'll if it's not out already. Well, if it is, here it is again, what up Wednesday? I'll go dig it out of the fucking archives. you guys couldn't have that. decent. Um, keep in mind that the CDJs at the radio station, where do Freaky Fridays are also very archaic? Um, I'm not complaining, though. I don't know. I don't know if I got to the episode where I was talking about that. Uh, or maybe I got I got fi I gotta figure it out. um I gotta figure out where these episodes are. There's like six or seven. Should I uh honorable mentions or dishonorable mensions? I feel like it borders on both. because I just figured out what apparently the six seven phenomenon is. And I'm actually worried about suburban children, like, having act like, why are they saying this? Because I looked up I looked up where it came from, it came from this rapper called scrilla dude. not gonna lie. One of my personal favorites, cause I love rap, that is terrible to a certain extent. um and it is, like it's not only it's not only like it's not lyrically terrible. He's actually really good um He's actually really good whatever he's saying. I know what he's saying, which is what's terrifying that, like, apparently suburban upper middle class and upper class children are saying this. six seven thing, because it came from this video by this rapper called Skrilla do doot. Yup. and well, it's culture music, like it's it's trap culture music, it's not necessarily drill, but it's done in the style of drill. um, talking about like the culture the culture the culture um that is not necessarily like great. cause he was talking I was like yo. what the fuck are children saying this for? Um, what the fuck are children exposed to this for? Because there was no, like parental block on it or anything like that. And the dude was talking about like, straight up murderer. He was like, yeah, m, like this though. And I was like, oh no, like I I actually kind of dig his music because it's it's like it's the music that was born of like the Young Thug and the low Wayne and themehesine and it's bad. It's really bad. Like it's really bad. like if your kids are saying six seven, like, the origin of that is not, I'm like,o, shout out sc a d do, because that is facts, but also like, like like kids should not necessarily like, everything he was saying and all of his songs, I was like, that's bad. That's bad that you said that. not that you shouldn't, actually. I feel like there, like art exists as a medium to be able to have this level of freedom of speech, and that's why it exists. But also like, if you understand which I think kids obviously don't if they're just like, oh, six, seven, I'm like, okay, like, but obviously, like, this is where that came from. Like, and this is where that came from, and the dude is talking about some stuff that I'm like what? Like, I'm not confused. I know what he's talking about. But like, children should not necessarily like, even if they don't know what he's talking about, this is not like, this is different from like, when I was like, 10 and it's getting hot in here. So take off all your clothes, like that came out or like to the window to the wall, like this is mild, those things are mild, compared to like, the shit that scrill a do dude. talks about. I'm like, oh, what? What? And apparently we little kids are seeing this and exposed to it, like, they don't necessarily know what it means, but he's like, yo, these are the lyrics to my songs. Listen. I'm like, oh, like. That's troubling. That that exists. That's troubling. truly troubling. I'm I'm not talking shit. I actually really like it, but like parental controls, like, my kids should not be exposed to this, like via the Internet. Like, you should not like, this should be something especially if you live in the subrooms like if you live in a house that has rooms, like if you live in a house that has rooms in an all. like the culture that this is referencing and you know what? The only thing that actually made me look it up was like so many people were saying it in the circuit of television that I watched that I was like, it was bothering me. It was bothering me like Labubu was, but Labubu was far less disturbing, far less. I was like, oh, no. this is not cool. This is not cool, David Letterman. This is not cool, because he was like,Yo, what's up six seven? I'm like, you're 106. I don't know why you're saying this. So I looked it up. So I looked it up, and I was like, oh no, like, okay, like we know it's a cultural fucking phenomenon, but like, do you know why? Do you know why? Like, do you know why? And do you know what this man is talking about? Do you know what this man is saying? Anyway. I'm not I'm actually not gonna say it. Like I'm not gonna say it because I think it it exempt exemplifies that's what I'm trying to say right yeah. I think it exemplifies and represents a part of the culture that is deeply, deeply, deeply, deeply wrong. um in the history of the United States of America. I think it's just bad news. It's just bad news. And it's bad news, like it exists, but the reason why it exists is terrible, like it shouldn't exist is it's terrible. It's bad. It's bad and it's bad that kids are saying this. It's bad anyway. it's really bad. Anyway, I got Peloton time, bad girls' club reunion, some coffee to reheat. Here's this song, um there's no anything else for a while. I gotta make sure that like my uh I got to make sure if I get taken out, it's by like a city bus. And, you know, not just because my insides are uh imploding. um and yeah, my insides are imploding. Uh, gotta take care of number one, which is me. So, that self serving thing I get, but, you know, I'm just not the kind to to step on heads or like, I'm not gonna make it, like, purposely harder for you to do something. Like, I do believe in free will to the point where if you're not hurting anybody else, it's not affecting anybody else's, like vibe, like, do what you want, like, as long as you're not objectively or subjectively hurting anybody. Like, just don't hurt anybody, but besides this, you know, take care of yourself, but it's not, you know. I mean, you're not causing any quantifiable harm. Go ahead and, you know? I, um, but that's it. That's that's it for me. Thank you for listening. Is that it? Yeah, forget me nots. It's not finished. I've got a lot to do. Like, I actually had this is a song that actually has like a list, like a handwritten list on a piece of paper of like do this and do that and do this and do that. But like here's what I have so far just in case, you know, the city buses be getting awful close to the curb sometimes. where I stand, I am yep, they do. anyway. um I said more stories to tell and stuff, but now it's not the time or the place. did I say my thing? Yeah, I say my. Dave you were listening. something, you're listening, see you next time. That's it, yeah. Yeah, I don't have anything else. Thank you for listening. See you next time, bye.

Now, and??? Okay! Just another dime, And just enough to find Before I count them up to dollars— But you're turning into wine. What did you ever want? This is my other world. Go shatter you tantric catwalk elsewhere! Don't you know there is a show to put on? A wool to pull over the eyes of the unknown? Why do you have to groan at the quantifiable harm known but justice undone. No harm, no foul No food, no valid excuse for betraying my sacred dopamine, but hopefully you know only no good But words can come from it, And words that fall on blind eyes have no context at all. {Enter The Multiverse} Uncorrected transcript. [excuse my neighbors in the background they're determined to make my life miserable more than likely in exchange for dollar signs.] Okay, my Wi-Fi is off, my Bluetooth is off. Oh, my laptop is open, my Wi-Fi is on. I can give me a second to remedy that. Hello. Hello. I'm Atticus's tail says hello. What's going on? Oh, I wasn't planning on oh, my WiFi on my computers off. That is good. Uh, I keep all my devices uh, at minimum on off the grid as often as possible. Um, there there actually it's crazy how much of a difference this makes. I gotta pour myself some coffee. it is almost midnight, o'clock. Hello, um, what's up, we're missing talking episodes. Um, we're missing talking episodes from season 12. I can't find anything like past October, and I know it's on one of my hard drives, but all of my hard drives are full, um, I have like something like 10 terabytes altogether of stuff that needs to be like moved around and not all of it. Some of it's like really personal, like not personal, but like sensitive information that I can't necessarily utilize a cloud for. So I am it's taking me some time to organize some stuff. I I try to do between like eight and 12 hours of just organizing on any typical night after my uh exercise or whatever, or between I would say that exercise is definitely like the primary function of like my life. And that's like the priority right now, especially with the things that I've been going through. I think it's really important to keep my physical and mental health as um in in it's not gonna be at its peak, um, because of the noise pollution that I've been dealing with, and it's actually made me really sick over this extended period of two times. um, and I'm trying to um seek treatment for that, but it's a uh it's a long road, I have a long road ahead of me. We could just say that. Um, which is why I am giving you guys, um, some stuff that I've been working on that's not necessarily finished, and I'm actually really like, I'm embarrassed because I don't necessarily um I I actually have a hard rule of not releasing any music until it's absolutely finished. like even if it is a first draft, like it still has to be finished. um, but I actually and I gave you, I think, I think two tracks, which is actually four. um because this upcoming project, it's a concept album called a symposia. um and the concept for it is um a lot. I don't necessarily have to explain right now. Um, but all of the tracks so far on it are double tracks, and so it is typically I've always really loved albums that have that are like gapless. I don't think through my distributor, like I can never technically um, like put out an album that has no um technical stop or start between songs, like they would have to be cut a certain type of way that, like my distributor does it. There's always gonna be a gap between my music, but um all of the tracks are um double tracks, so they're all two tracks in one, um that are kind of along the same theme or idea and um like lead into the next track. I've always loved albums like that. uh, one of my favorite compilation albums, um like just to give you an example, just to throw it out there, is like, the Beatles love album, which is not actually a Beatles album. It's just a, um, it's a compilation of their um songs made for the Cirus Sole show that I think is still playing in Vegas. I don't know if it is it's been playing for like 10 years, and I still haven't seen it. um I really I really want to take mushrooms and go uh see that show. I've wanted to do that since it came out, but my favorite one of my favorite albums in the world is the love album, which is is basically a mash up of like their greatest hits, crafted by, um engineers and people who used to work with the Beatles and stuff for this uh Cir dis soet show um in Vegas that I hope I get to see I hope it's just one of those like long standing like like Siegfried and Roy. I just realized that they were in Vegas for like 40 years, like they were just there, they were just a stable, so hopefully that show is um kind of like that and one day I'll get the, uh one day I'll get the opportunity to see it. Like my my bucket list, like destination, like vacation at one point was to go see the Beatles love on like an EDC week. um that's still something that I want to do. I promise myself I wouldn't go to EDC unless I like ever got booked there. Um, and I think this year is like 30 years or something of EDC, and so they um they sold out in like five minutes. um so it's it's not it's not something I'd consider doing by myself anyway, unless I was gonna go with my best friend, and um and I was like I was talking to my best friend and I was like, oh, maybe I should check on, like the early bird tickets for ADC, and they were like, they was sold out, and was this celebrating 30 years, and I'm like, okay, well, I guess I should uh work on getting a booking agent, but my music is not my music is kind of turned into like a passion project. um, since everything that I've been going through over the last couple of years kind of just like took me off my path in that sort of way and DJing, I kind of wanna preserve it as like, I really love being a DJ. I really love producing music and because it's so consumer, there's a bunch of people in the industry that are not necessarily like music oriented or love oriented, and it's just like a whole different vibration from like the peace and the love and the unity respect of that. Like I like the scene for. I really want to check out, like as far as a festival goer is concerned, I really wanna check out some of these new festivals that are popping up that are doing like no cell phones. I kind of wanna check those out, cause I feel like the quality of of the experience has been preserved or will have been preserved in in certain spaces like that, um, but anyway, I'm uh I have been physically ill for like a few months now. um, and so the best that I can do for you guys my audience just because I'm not sure if I will get symposium out this year in which case it will come out next year. um, and then I think this track, I'm not sure, this track is definitely like a track that was in my mind. um implementing all of the like sound design stuff that I'm doing for symposium and is also a double track. um it's called Forget me nots. uh and then the second track is followed through. uh,get me nots/follow through. I think it's like an eight or nine. um minute track or whatever. It's not finished. Um, actually, the only finished track that you guys have heard, and even this even bitter butter and southwest of your scars is like a double track that is finished, that is on symposium, but it's still the version one, like it's not um I haven't done like any of the final mastering or any of the things that I do in the process of getting ready for a a release. I do have like a a like an implemented ritual structure of doing things like that, even for projects that seem like mindless, or, you know, things that are seem seemingly just like thrown together, like chasing dragons, was kind of like not necessarily even a concept until the three tracks were like sandwiched together, and I was like, oh, okay, like, this does tell a story and and they were all created in a certain way so that they'd go together. I think I fixed that. um, because, um, chasing dragons, the EP was for some reason, when chasing dragons got released to, like all the major platforms, it had chasing dragons was the first and the last track, and then dishes and the sink was just in the middle, which was weird. um so the third track on chasing dragons is actually immortalist and I got that all fixed. and I also got the regular like the normal version of the songightfall is out on the platforms now. Those were two er errors um that I needed to fix that I finally did. um but I'm slower to do music things now because like I said, my health is the priority. So it's like, yo, if it comes down to like getting a good meal in or like some good exercise or like right now I'm doing active recovery because I'm dumb. I went from like not really running anymore and only walking for an hour every day on the treadmill and doing like an hour between one and two hours on the pelotone, a day which is technically still three hours of work, um, but then I went back into heavy training the way that I preferred to do like I prefer to be at the gym between two and three hours every day. That is my ideal. That is where my body feels comfortable, um and flexible and like happy. Um, and if I can do that in the very beginning, like to start my day, cause I don't necessarily have 24 hour, like days anymore. um like what's technically the end of my day is oftentimes the very beginning of other people's days, and so I'm kind of just on on night, like, routine because it is like, I'm I'm basically just like protecting myself from the uh, you know, like my my nervous system can't take any further damage. Like, I do have really pronounced synesthesia and, um, I wasn't necessarily like planning to be exposed to extreme like noise pollution for an extended period of time without having the financial security or stability to escape from it, cause honestly, if I could have moved, I would have moved or if I could have just left, I would have just left, um, but I obviously wasn't in a situation that I could, and so I became very vulnerable um, to this type of attack, which I learned was actually very common. It's not something that is just like, oh, you know, um, this is just something that I'm going through. It's actually a very common for people of color to be, um vulnerable to this kind of disease that comes from um an implementation of using sound as a weapon. And I mean, like the irony is is that I was already kind of studying synesthetics and the way that, you know, as a culture or the way that in as as far as like mass consumerism is concerned, that's why people pay so much for a, you know, festiv for the festival experiences because sound can be a very much uh manipulated to be a physical thing. It's not, you know, it's not invisible. And so the fact that those same kind of um those that same kind of engineering can be implemented also in a negative way to have a negative effect. Like, you don't have to punch somebody in the face, like, you can just back up your exhaust, your engine exhaust, and, you know, fire at point blank to somebody that is, you know, caught off guard. and in that way, um sound can be used as a weapon, it uses the same dynamics, the same kind of dynamics as, you know, the reason why we go in the th you know, in flocks by the thousands and the millions to these festivals to feel the vibrations that that are on the opposite end of the same spectrum, the healing vibrations of, you know, certain things. and so I've been doing my best to try and, you know, maintain a certain level of health through, you know, using, um, you know, certain frequencies to block out. But when it's your physical person is in a space that's being manipulated to be on a certain frequency, um, uh, the exposure to this negative frequency that is unnatural to your body over a period of time. um, you begin to get very, very sick and that's what's happened to me. And so I'm trying my best to like keep my head above water and, you know, stay afloat. Um, but I didn't expect it especially after, you know, a period of like two or three years before that, where I was just like on the go all the time. Um, and, you know, not necessarily having like a a suitable foundational stability or a place to call home and then going straight into something else that was like more traumatic and more violent than, um then I expected, and so I've been trying to remedy that. um, the best that I can and because I'm putting my mental health and my physical health first, I'm not necessarily like, I it was weird. I was kind of in like a meditative space and I had, you know, like this this kind of spirit come over me that was like music, you know, music is gonna be there forever. like, as long as you're as long as you exist, you know, whether it's in like a physical realm or like an infinite realm or whatever, like as long as you exist, there's always gonna be music. and that was kind of like the sign that like, K, as much as I do like having a streak of, you know, like being an Ableton every day for several hours a day. um, the way that I am using these techniques that I'm applying in symposium and as seen on TV, which reminded up being a double album, because I actually have, um, like several, um, tracks that are like honestly on TV, I've been working on since, like, 2023., like, early 2023. Um, and so, the things that I've like collected, it's kind of interesting because my evolution as an artist or like my technique as a producer will be, um represented here in this project, which I hope comes out next year, but I can't say for sure, cause it's probably the it's definitely the biggest, most um important album I've ever worked on and I I put a lot of care and thought into those as seen on TV tracks because it does um like creatively, I guess, run alongside this series into the multiverse and all the series within the festival project, uh Ascension Death Wish, legends, um the legend of uh, the secret life and the sweet life of sunny Blue, just to name a few, there are I keep trying to make like a list of all of the shows within the festival project, but then I'm like, oh, like there are so many that it would it just falls apart. And so I mean like I'm getting a little bit more organized with the with the actual structure of, like, the television and movie, like, script part of the project. um, while I'm cleaning out my hard drives, but having to organize everything so that it's, you know, so that I can go to a certain hard drive and be like, okay, well, this is um, you know, this is this season to this season. I'm still archiving episodes from, you know, 2021 and and because a lot of those statistics can't be like once I delete an episode from the podcast, it goes away and all the all the statistical information about the number of downloads,, like all of its information, all of its metadata goes away. and that's very important for what I'm going through in my personal life right now in order to protect myself for those things to be taken down, but also for it to be archived in a way that I can reference as a creator like, okay, this is this day that this was published with this, that like, because it's it's a time travel concept that is multifaceted, and it is like based in this multiperceptory m multiperceptory multiimensional concept of technically technically infinite time and space, like it has to be organized in such a way that, like, all of the series and all of their all of the ways that they're connected to any particular parallels have to be, you know, they have to be organized and documented so that because I'm the more that I'm looking at it, the more it makes sense. I'll be like, oh, like, I thought this was just like nonsense or whatever, but when I'm putting it into like an organized space, um, and to me, that's like the god part about it is that like, oh, like, um like, I' I'll be looking at the writing and noticing how it takes like particular shapes or how the shapes will cut is sometimes like make pictures, like sometimes when you're looking at the clouds and you see, you know, shapes and the clouds. sometimes the riding for this project is like that, which is kind of incredible to me.c it's not something that I'm doing um, intentionally, it's kind of just something that's happening. I'm writing in a stream of consciousness that's also, you know, like artistic, creative in a way, that kind of has this, like, sense of divinity to it that I'm not necessarily, like, consciously doing. Um, so everything has to be organized in such a way that like it is gonna take time, um, and because it takes time and a lot of the other things that I did not foresee happening or also taking a lot of my time, like a lot of my my time and energy to document like how sick I've been getting a lot of time and energy has been focused on just like, doing the research on, you know, like crazy crazy shit that I never really took interest in, um, but could be applied here. um, could be applied to this situation and and kind of just finally being able to have a piece of mind to give myself the benefit of the doubt that, like, it wasn't in my head. like, I just had to be uh, I just had to be pushed to the point that I could understand, you know, that this um, sometimes very silent type of, um, you know, warfare is is like a documented not even necessarily historically, but like presently and present day. um, they're just I don't think haven't been enough survivors of this kind of thing, um, that it could be, um that it could be notably researched, like the amount of reports, but, you know, it's it's not it's not by choice, like it is taking up a lot of my time and I wish I was the kind of person that could just ignore it. Um, but I'm getting very physically ill. Um, so I can't, like, I can't ignore the fact that, like, you know, I'm running on zero pretty much all the time, and that my my patterns of speech have changed in my, you know, my thoughts have been intercepted and my, you know, like, because physical and mental health is such a priority to me, the fact that those things have been the primary uh, source of degradation has has affected me in such a way that it's not, I mean, like, it's less emotional than it is the logical answer to, you know, like if you have a cold, you take cold medicine or if you have the flu, you take, you know, it's it's like, well, remedying something that is a fi physical illness, you know. um, removing the cancer from the body, uh, you know, in such a way that it doesn't come back is kind of my main primary concern in this way. Um, so I am am especially because I can't but the talking episodes are actually more popular this season than any other season. and I can't find like six or seven of them, because I I don't know, I was just switching out all my, you know, uh my stuff so quickly and pulling things out of the cloud that it, you know, got saved under drive zip eight, seven six nine, you know, like. It's it's just a mess of of terabytes and tabyrites of creative work, um, and, you know, other things that I've had to dedicate my time to, which is not necessarily fair, but, you know what they say is life is not fair. Um, so, you know, life hasn't been fair, but I have, you know, been blessed in such a way that, like I I I've at least been able to um creatively channel some of the some of the energy and some of the time that I have left over that is technically mine. while in the sense that I've had a lot of my time and energy just stolen in siphoned, um, you know, I have been able to kind of forge a medium through fighting this that allowed me to, you know, start doing art along the lines of, um more more the way that I want my music to to think and feel. And so I'm I'm still just working from a little tiny MacBook air. um, so my, you know, um, my projects get like overwhelmed really quickly. I can't necessarily implement all of my um my plugins or all of the tools that I like to use at once, and so everything is kind of segment segmented in the way that I'm working. um and like, yeah, my projects get overloaded very quickly. um so the tracks that I'm giving you are not finished, but they're more um I would say like they're more, like colored, they're more like filled out. It's not necessarily abstract in the way that some of my stuff is like very like, you know, like drag and drop and cut and go, well, I do a lot of like, even in my even in my like my cut and dry stuff, I do a lot of sample manipulation. I very rarely will keep a sample in the way that it is without doing something to it, you know, like, I don't do dragon drop, um, unless I'm planning on just, like, you know, giving a beat to a rapper a artist for free. like, sometimes I'll just be like, okay, for the next 15 minutes, just do, like, something, you know, like a two or three minute, like dragon drop or whatever. But those those are not necessarily tracks that I A share here or B like plan on doing anything with because the world of sampling has gotten to the point where it's like, yo, you gotta have some creativity, like you can't just open up a sample pack and drag it and drop it into place, because then you have eight or nine songs that sound exactly the same. Eight or nine songs that are the same because basically you're just putting together a, you know, you're putting together stems from a track that was already created, you know, by somebody that's trying to sell you something, so um, you know, I I take a little bit more creative uh integrity in the stuff that I do mean seriously. Um, a lot of it lately hasn't been serious, but I I actually did want to take an hour to talk about this not this track in particular, just talk about why I'm doing this because it was something that it was like, oh, I feel like this project is a little bit more special or is a little bit more like technical than some of the other work that I've shared here on this podcast or work that I've put out before and so I kind of wanted to keep it to myself um, but then I've kind of had a couple, like, you know, like heart shattering experiences that make me realize, like, you don't know. like, you don't really know what's gonna happen and life is, um, sometimes very cruel and sometimes life is, you know, it just takes turns that are not necessarily. um you know, like you don't you don't ever know. And my mindset has not necessarily been that negative. It's like, oh, everything, you know, there's a there's a reason for everything, and blah, blah, blah, and I still do believe that, but like, you know, two years of constant, like, torture and stress to the point where I don't necessarily have a medium for support or, you know, um, like, I don't necessarily have the foundation of community. um, being in a place that is not my home and coming from a family that's very, very small and doesn't necessarily have, you know, well, like, I don't have what some people have, I don't have a large network of family and friends and the kind of family and friends that you create for yourself in the business are not necessarily, um, you know, like people can't necessarily be trusted to have your best interests. Um, especially especially if you are coming from like a a margin for success that, you know, is documented, like you've done well, you can't necessarily still believe that, like, everyone in your immediate circle has the best interest for you, because it is in human nature that everybody has, you know, themselves as the primary interest, and so um, me being like a a solidly um you know, like self sufficient. I won't say independent person. um, driving towards independence or whatever. um, but being a person that spends a lot of time in solitude and with enough respect, like enough self-respect to understand what my when my spiritual and my personal boundaries are being pushed even even in a person you know, professional setting. um like I took today for active recovery because I'm dumb and I went straight back into training as if I'd never really stopped. like it okay, like I'm on the Peloton seven days a week and I have a treadmill that I walk on in for an hour a day, you know, five to six days a week, but it's not the same as like being in the gym and lifting in stri strength training and and um active recovery um but I was like, okay, if I was running like a Madonna or whatever, you know, for this amount of time, then I should be able to do that. I should be able to do that. No, I didn't run a Madonna, but I ran like a 3K and then a little bit. and I like, my body was like, yeah, this is good, but then I had, like the rest of the day and I did not properly hydrate, and I got, like even more sick. and so I'm like, oh, fuck. Like, I really got like I really got a prioritize, like, my physical health, because if I keep letting myself get pushed, you know, like over the summer, before requisite when I was just like, oh, you know, like, I'm just gonna record. I'm gonna go to Manhattan 20 fucking days in a row and not take a day off and I'm also gonna train, you know, and I'm also gonna do this, like the like, I'm maximized my potential for burnout, which also left me per like, personally vulnerable. to the, like, professional sabotage and, like, weird, underhanded, like, underbelly shit that, like people in the DJ circuit are doing because it's so hard to actually break through., from the level of like consumer professionalism right now. So people are doing like a lot of nasty things to try to get that main stage spot and I wasn't like in my head, I'm still very much like a Disney kid, like, I'm still like, I don't necessarily well, I mean, like Disney to teach us like, there's always gonna be a villain, but like, a society kind of undoes that teaching and is like, but that's just in movies and that's just in your head, but there's no like to me, I there is just this weird misst up between real life and what is told that like, okay, like anything that exists that is like in a certain field of negativity is just in your head. but, like, evil is it like a documented source of the opposite of good. since the beginning of time, and I just don't understand in how in a society we can philosophically and psychologically embrace therapy, however, when it when it comes to, like, real lived experiences, when you're dealing with something that is not necessarily, uh, like a normal part of societal living, like that stuff only happens in movies. I'm like, but it does happen. Sometimes you just have to, you know, like being having I've I've never really been such a socially dependent creature. like, a lot of people have to have some kind of validation. That's why social media is like ruling our society right now. is because people have to have the validation or the likes of whatever they're doing is like cool with the rest of the group. and to me, that this is dangerous group think. like, if you're all thinking the same way, then there's something being missed. There's always something being missed, you know, if you're all on the same frequency or the same form of thought, you know. And so, I've always been like a big, you know, maybe it's just because I don't have any siblings. I've been like a big believer in embracing, um, independent thought, like, okay, if everybody else is thinking one way, then what is the opposite of what everybody else is thinking and not necessarily alluding to the fact that the opposite might be the right thing, but anything between whatever the group think and the opposite is, is also like valid, could be valid, you know, it's not necessarily the opposite of what everybody's thinking, but it's somewhere along the spectrum of maybe that or maybe the opposite, like it could be anything else in between. And so I think I'm the kind of person or the kind of thinker that's motivated by the the spectrum, you know, the spectrum, uh process, anything in between, like not necessarily that, not necessarily the opposite of that, but like what other possibilities, you know? um, could be validated or verified through thinking outside of the box or outside of a you know, being forced to the point of conformity that, like, everything sounds the same and everything looks the same and everything has like a way. That's not necessarily wrong. um, but also not necessarily the only way or right. um, so that I' of been uh what what did I get on that round about? I don't know. I've just been playing with like a lot of different concepts, like not necessarily trying to sound like anything. or anyone, and also not necessarily having the opportunity or environmental expression, like the space to be able to sound like myself. Like I still don't artistically or musically think that I sound like myself. um, and that they are elements of myself there, but it's something that's kind of, um, in its, you know, convex form of being this thing that is potential, but not necessarily fully realized or realizable yet. Like, I haven't had I haven't had peace and I haven't had like full p I haven't had peak health in a long time, or a safe environment in a very long time. and I think that the disallowance of comfort, not necessarily the safity of um of complatancy, you know, or or being comfortable to a point that it's it becomes dangerous, um, but just being able to kind of be in a life that is not necessarily like violent or terrible all the time. I think removing these barriers has not necessarily been a foreseeable reality for nearly a decade and while some artists technically thrive in what is, you know, what is this, you know, tragedy and darkness? It's there's only so much of a certain space that my creative ingenuity can take up and not void. And so, understanding that this time is kind of transitional in the sense that eventually it has to in no matter what direction break free from its current state of, you know, entrapment and its current state of imprisonment. um and so in my artistry and not will change, but I don't think I don't think it's necessarily going to be like fully realized until I have a a a point that I'm in an environment that I can breathe and be and think clearly without the force of control or being subjugated to, you know, a certain level of violence that's not necessarily always physical, but is certainly not, um, you know, without it's notable, um, impact on my physical health, my physical and mental health. So that being said, um, this track, um, this track is somewhere between symposium and, um, as seen on TV, I think I began writing it before the concept for symposium was fully formed. and, um, I think it was like the first of its little group of double tracks and I didn't necessarily mean, like, for the story, cause it, you know, ideally, like a song is like five minutes or less or whatever. um five minutes or less or whatever, but I've again, not been, uh, trying to conform to what is supposed to be this, or what is supposed to be that, and, um I don't know. I I began writing it in with the mindset and the technicality of symposium, but also as I listen back to it, um, I'm also using elements that have been implementing for the last few years into as seen on TV. And so there's some like to me, it's very beautiful. Again, what what is more important or more, you know, like wh what is more palatable for my audience is always differed like my favorite tr tracks are not your guys's favorite tracks from what I'm looking at for for the numbers, you know, my favorite episodes of me talking are not your favorite episodes for me talking. So, I mean, like they're exists here, this obvious, like, it's weird because a lot of artists can be applied to their fans and to their listeners. It's like the the listeners are being projective of like they see themselves in their favorite artists, or they see themselves reflected back through an artist that they, you know, like Taylor Swift, like, all her fans are Taylor Swift and like, most artists are that way that, you know, they're reflective of the people that they look like and have the same experience of and that's how, you know, um, that's how mass that's how mass media works. It's reflected, you know, through the medium of sorts, you know, um it as a as a concept that is shared amongst all all of those, you know, people. um, but I'm looking at my numbers and I'm realizing that, like, oh, there there's like a distinctly different flavor from the way that, like, my perception of what is my best work is and what my audience thinks is the best or, you know, the like I look a lot at the numbers not as they happen, but like over time, whereas I'll be in hiatus for a certain amount of months and then I'll come back. and see what the numbers are reflecting in in what is more, you know, palatable for my audience, like what my audience is is actually agreeing with more is like my better work and it's always not it's not necessarily again, it's not necessarily opposite. but it's not um, you know, it's not always what I expect to be. So this to me, I like um, but it doesn't necessarily like that you, whoever you are as an audience is gonna agree. Um This is actually the least completed track. um I feel like I'm showing you yeah, like I'm showing you my my uh it just it's naked cause it's very much not done. This is probably the most incomplete thing that I've ever, like, put out for anybody else to listen to. Um, but just being audit honest as like a person, not like as a entertainer, cause I don't necessarily see myself as that anymore after these couple years. Um, but being honest, like as a human being, as like a person, um, I've had some times that feel as though are, you know, an indication of not having a very prolonged experience in this sort of way. And I don't, like, I don't wanna put a trigger warning on anything. And I don't wanna, you know, like I I also don't want to insinuate things that are not there. Um, but a lot of the time, that is just to say that I don't feel safe, um, that I don't feel, um safe or secure, um, and that there's not necessarily a like sh it's just New York City. There's no level of like autho like a there is no necessary authority complex that has any sort of like, ability to protect you, you know, from uh certain experiences that are not necessarily um, you know, there's there's no level of protection from from, you know, there there are more heavily funded organizations that are like banks and investments or are more funded than the police. So when you're telling the police, like, hey, I'm being, you know, stalked or harassed and like, there's a pattern and like, here's the evidence and they won't even look at your evidence. Um, even though technically by the law, like it is, you know, documented uh, verifiable, like verifiable, like, no, there's none in my head. Like, I have like the videos, I have pictures, I have audio recordings of like this is happening to me, and they won't even look at it, um, not necessarily because they don't want to, but maybe because they've been trained to look in the other way. Um, and then, you know, just the cultural disadvantage of like, youre snitch. I'm like, I'm also within inches of my life sometimes. and nobody's helping me. Um, and it's not necessarily a mental condition. I think that more now than ever, I would be like readily willing to admit like, oh yeah, like, I should just take the meds, but I'm like, this is I'm not hallucinating this. I'm not gonna take some kind of fucking pill for some kind of medication for something that's like, I'm experiencing this, and not only am I experiencing this with like my eyes, my nose, my ears, like, I'm now videotaping 100% of my life everywhere I go. If I walk out the door, I'm recording, like, that's how many times I've been stalked or followed. Like, if I walk outside of my apartment, like I'm I'm videotaping it, because if I don't, if something happens, then it's literally their word against mine. and the police is, like, literal their whole thing is like, if we didn't see it, it didn't happen. Like, you can get you can get, like beaten within an inch of your life and the police can show up and you can tell them and they can see you like bleeding from the face or whatever, and be like, that guy did it, but the police will straight up tell you. the police will straight up tell you like if we didn't see it, it didn't happen, like we can write the report, but like we like they will not investigate. Period. They will not investigate. And so understanding that, like that opens the, you know, the possibility of like way, way more heinous crimes, you know, being able to be, um, played out without, you know, without any possibility of you having help for that, as, you know, is like dangerous to me, and a lot of the time I feel like I'm in danger, um, to me, and so, my priority is not sitting down in Ableton and and you know, getting these cues just right, like, especially with this this track. um, like it's so, so far from complete, but when I hear it, it still sounds it sounds decent enough that, like, I'll give it to you guys just in case, like like the least sometimes that I feel is gonna happen is that I just get hit by a bus. uh, which does happen almost any time I go outside. It's like, I will not get a bicycle. I won't because I'm like, that's like the easiest way to ensure that I will get hit by something. I'll get hit by something. um I will get hit by something, so I don't um I don't, you know. I'm just trying to, uh, get along and protect myself and away that, you know, maybe possibly enables me to, like, disappear. I don't necessarily need to be anybody. I stopped fighting for that main stage spot a long time ago, cause I I see that it's not about like it can't necessarily be about the love when it's about the money. and I have so, so much love. like for the music, um, and for what used to be the scene. I mean, the scene's always been kind of dirty. You pick up any book about DJ culture, about festival culture, you know, about music in the in the sense that it's been meant in the rave world has always had like a CD side to it. um because it was previously a counterculture, you know, that became mainstream and it still definitely has its like flavor, it definitely has its like, you know it's flavors to it, which, you know, is is a magnetism or like a draw, that's like, oh, there is this darkness that exists, but like, at the core of it is the frequency, you know? And I think that if there was ever going to be like a place for like a placeholder for success for me and the industry, it would be somewhere in the future when it can be a more decisive. No, what am I trying to say? Oh, I don't know. I think that money really fucks things up sometimes, and because of the amount of inequality in the world and the fact that the the world has become such a competitive space, um, that there're actually less places for opportunity for artists, even though it seems like there should be more. um I think until it's like about wellness, yeah, I think in until music can be until we can create like spaces where wellness is like at the center of these, you know, gatherings, then I don't think it's necessarily going to be like a safe place. Um for anybody, but let alone for me, because I'm very much like a fragile person when it comes down to, um, like per like the protection of my spirit and the protection of my aura, I don't necessarily want to be in a place of uh tragedy or a place of defense all the time. I I wanna go outside and and be in defense mode 100% of the time. I am right now, so um, like anything I I I kind of take it with a grain of salt in the way that like anything I say can and will be used against me. And so I don't say so much. I I don't say so much, and I want to be sure to take care of my art in a way that it doesn't is not, um, you know, so that it doesn't necessarily exist in a place of toxicity or that it's not coming from. Like, I won't sit down and Ableton if I feel a certain way. It's not just me being lazy. Like it's if I have like a certain vibration that's incurable, like it's not uh it doesn't make sense for me to, like, you know, sit down and work on a track. So this this track, uh, forget me nots and follow through. um, I think it is the first track and symposium. I don't know, because when I listen back to it, I also hear um when I listen back to it, I also hear as seen on TV, like a lot. um like a lot. And so it's kind of interesting to see those two kind of elements of my artistic personality combined, because I think the tracks that I've shared with you that are from symposium or different in the way that they're um made only one way, but this one is definitely implementing um techniques from two projects. Um, so the what are the two other ones? I think it's like talked to me about it. Is that oneosium? I think so. and bitter butter and southwest of your scars. Ah, those are all from this project, but then I I look at this one, which is technically the first of the bunch and it's so not done. that I'm like, don't put it out until it's done. and I'm like, well, and might not ever be done with the shit that's happening is kind of scary. Like, it's I might I may not ever be able to get back to a place where this is possible because of the things that are continually happening uh, to me. Um, I I don't know what the source of evil is. Like, I really don't, like I am very much a spiritual person and I do have like the tendency to believe that like no matter what God has my back so if I'm removed from one situation or existence into another, it is for the protection of that aura, for the protection of that frequency, for the protection of, you know, keeping my, you know, um my source intact, like there's, you know, certain elements or certain frequencies that can't exist in in other realms. I think that, uh, a toxic environment. Like my energ is not going to sustain an intoxic environment. It's just not. It's just not. It's not necessarily even a personal or emotional preference. It's more of like a oh, this doesn't go in there. Like this doesn't go there or I don't exist over there. Like, I don't, you know, it's not. I think I wish that I could be applied to like every space and time, but I think that there are certain drawbacks to being in energy that is applicable to anything and everything. I think that, you know, in the very rare circumstances that an energy like that exists, um it's very magnetizing, it's very, uh enigmatic and it's very charismatic in the way that, like, everybody wants it, everybody wants a piece, everybody wants to be around it, but also for that person, you know, where that energy exists, you know, for that vehicle, I think that it becomes like exhausting to the point that, you know, um, the human of of that, um, you know, the human of that energy is entirely vulnerable all the time. And so those people that are, um designated to do those kinds of jobs, having that high level of power and energy are also, uh, you know, in every sense of the word, um, like exhausted to some effect, um, and I'm exhausted, um, but I think that this last two years has been a case study for all of the like I mean, like she's just horrible things people are doing to each other to try to get ahead, you know, like to try to get a little bit of the pie just to get the tiniest crumbs or to get you know, people are stepping on heads out here. Like people are doing what it takes and they're justifying things that are technically morally, you know. so very morally, uh, corrupt and so so so bad to other people with the justification of like, that's just the way it is. Or you you gotta do what you gotta do and I'm like, yo, dude, but like again, my energy just does not exist in that space for that mindset you know where it's like you know, um because I also believe that like a certain level of justifying, you know, morally uh, you know, morally corrupt behavior eventually just makes it so that you can't get ahead. I I honestly chronically believe that, like if you're constantly fucking other people over just to get to the top, like your top is not going to be consistent with what is actually success and what is actually um freedom, you know, like, you are gonna owe back energy to a certain extent, you know, um, because you stole it in the first place, like, you can't you can't sustain on stolen energy. Like you cannot do it. Like you cannot exist in a place that that was taken from somebody else without something else in turn being taken from you. I honestly truly believed that with every like with every last breath, with every last word, I honestly believe that like that that good overpowers evil. Like, you can't sustain on something that you robbed from somebody, you can't sustain on something that you you know, that that you took, eventually, you know, karmically, um, it comes back too, and so, I don't think energy is any different. I think if you suck the life out of somebody, eventually something' gonna get sucked out of you and, uh, it's one of those things where it's like one step forward, two steps back for people who uh subsist on energy that way. I just I don't know. um, I try more and more to be conscious of my self to point where I realized that um the effect that I have on people could be, you know, long lasting. It's it's something that could be like a ripple effect, and so I'm very careful with my energy in the way that, you know, I if I dole it out, I expect I expect 39%. I don't know why that's the number. 39% to get it back. um, you know, on a certain way. And uh understanding my limits and my like just understanding my ability and my placement. understanding the, you know, the the love you make. yeah, all that. and the love that you make is equal to the love that you take. And so um also, I think that love in itself is probably the most valuable heat source and that it overpowers what is um technically needed in the society of, you know, for survival. I think that love overpowers, you know, whatever material, you know, the material sense of existence is. I think that love overpowers, whatever is morally corrupt, whatever is systematically corrupt. I think that love at the end of the day, like, really does put in its place. um what is supposed to be and what is not supposed to be. And so in because I think like living in this spirit with the understanding that like it took me a really long time. I think I having a a a victim's mentality of like, I must deserve this in some sort of way, but then understanding also like I didn't do anything wrong. Um Sometimes these things just happen and the understanding of why that is is not always attainable. Um, and so to wallow in it and to be like, why, why? You know, like, why? I mean, I think in a from a philosophical standpoint, I do a lot of this because it's like this doesn't necessarily make sense, but it has to it has to be an art artistic way for me to be like, well, it doesn't make sense, but like, you know, now I have ten pages about trying to figure, like, instead of actually just wallowing it and being like, what? Well, now I have ten pages of like this, you know, something that can be considered beautiful. you know, something that can be considered, uh, useful to somebody, maybe not now, but at some point in time, you know, because all of my work is is stored in like this digital time space, kind of like encrypted into history in itself being like a digital marker for, you know, something that very much did exist or did happen. I still believe I still live in the belief that like this, well, it's just like the overall knowing that this part, this faction of history is a very, you know, uh verifiable part of ancient history, you know, to a culture that exists like beyond our time. And so with that understanding that, like it's so crazy, because I do have this overriding kind of factor of, you know, God that's just kind of like, oh, these are ancient times. this is an ancient world and it's hard to like wrap your mind around it because youth, you know, you think of yourself in the present time of like being a, you know, a being of existence in the future. Oh, I watched the jet the Jetsons. Oh, that was so good. I watched uh the Jetsons. which I didn't know is also the Simpsons. and like every animated show that came out on it like a lot, actually. It's a good show. I got I think I gotta watch it again because I was like, oh, this is like ten different shows. It was like ten different shows. um but I watched like the pilot, I think episode of the Jetsons and I was tripping. I I was tripping. um it was just really good. Anyway, um I think what what was I saying? Oh, like this time being like a marker for actual actually being a primitive civilization. Whereas like not necessarily compared to what we know as the primitive civilizations, you know, of human time, like, you think of primitive civilizations of being like the ancient Egyptians or, you know, the Mayans or, uh, you know, the Greeks, uh loved them. I really I I almost even favored them over the Romans. almost, almost, almost, I don't know, I could talk about history and culture forever. cause I'm like, but the other Romans really, like their architecture, but the Greeks more culturally, like artistically, I think where what is the word for them? Uh, the Greeks? What is the word for them? I think there were definitely more, uh yeah, yeah, definitely more artistic philosophical than the Romans, but the Romans had like a lot, like a lot to do with modern society to the point where that's also uh admirable. I do like the Romans. They're just like shitty and violent. They're just shitty and violent anyway. um what was I saying? I don't know. I'm wrapping this up. cause I'm hungry. I don't know about a taco, though. This is technically the start of my day. at midnight o'clock. Um, at midnight o'clock. oh, that's what I was talking about. Markers for ancient civilizations. Oh, yeah, this this time is so so far beyond. But I think the the incredible thing about this time that we're living in now presently, um, is that it is so, like there's so much record of it that it does exist beyond our time for, you know, potentially millions of years and into hire and further civilizations. So I kind of live with that, like, understanding of like this this also and itself being like, a part of the ancient world as far as time is concerned, you know? like, in as much a stipulation of like any apocalyptic or societal, you know, destruction is made, like nothing really sees past, like nothing really sees past the fact that, like, they're so much historical information about our present time in the future that it is consistently creating to an adding to like the what am I trying to say? Oh, something about the multiviverse. Something about the cosmos or something. constantly expanding, because it is, but whatever, I actually just kind of made this as a real time episode to so that I could share this song and then um not really like I don't necessarily have anything for you, anything else for you in this season. um it's there. like, there are six or seven other episodes. There might even be some music. oh, all the freaky Fridays or whatever, mix tapes. Did I even post what up Wednesday? I did I did a freaky Friday on a Wednesday and it was arguably the best. of all the freaky Fridays. I don't know if I posted that already. um I don't know if I posted that already. but it's not. Also, like my podcasting distributor is kind of archaic. So it takes a lot of work just to go check on what's been posted or whatever. um So I'm I'm not going to make any promises and be like, oh, go check if that was posted. And if it is posted, I'll just maybe post it again, cause it's worth it. Um, what up Wednesdays? I did it twice, actually. um because it got difficult to do freaky Fridays. It's still kind of fucking difficult to do it. And, uh, I it pains me to realize, like, how physically affected. I've I have been. um cause it sucks, cause it's not just something that's in my head, it's like ow, like, my body hurts. like, I cannot, you know. I can't withstand a certain frequency or electronic exposure that is negative over this much time. Like, I'm just like broken down right now. Um at least I'm still capable, cause I didn't ever think. I was like, I don't think I'll ever run more than a mile again. Um, I probably should um take the proper steps to make sure that, though, uh, now that I'm running again, I take the proper steps, like, I forgot to stretch, and I forgot to drink water. Stupid. Well, I I just felt so good to run. I love those woodway treadmills so much, so much, it just felt so good that I didn't that I couldn't stop and then when I did, like my body is like, okay, like you're stupid. Like it felt really good, so I'm like, all right, like active recovery. I'm gonna do like two hours on the pelotone and then a walk. um, before I run again. and that's what I'm about to do right now. I love getting to the reunion parts of the bad girls club because as the most fighting and I burn the most calories during the reunions, I just finished to season. I just watched the season for the second time. and uh I have a reunion episode coming up, so I'm a I'm— I don't know. I'm pretty boring person to be quite honest, but here's the song. okay, I'm at an hour yet. Here's the song forgetmenot// and follow through. It's not finished. Like if I could give you a percentage on the— what are you doing? Yo, this dudes are weird all day. I'm sorry. Um. He's so funny. He's so funny. Earlier he like earlier he like sneezed. Earlier he sneezed. But like also farted and this scared himself so bad that I could not contain myself. Because he was like embarrassed. but like, also he sneezed and farted and probably could not. He was like, oh, my God. Like, oh my God. And then, uh, I laughed for like a good five minutes after that. He seemed genuinely embarrassed. I was like, yeah. yeah, that that is shocking that you can manage to do something like that. like being a cat, but, you know, oh, he did. It was good. That's why we have emotional support animals, because I needed that laugh. I don't think I' laughed so hard at anything in a very, very long time, so I'm glad I have my little kitty. my satterat, my Mr. Cat, mush matters anyway. uh, was I wrapping something up? I was.ive meods to follow through. this song that's about to come up, and then I'm maybe I'll maybe I'll if it's not out already. Well, if it is, here it is again, what up Wednesday? I'll go dig it out of the fucking archives. you guys couldn't have that. decent. Um, keep in mind that the CDJs at the radio station, where do Freaky Fridays are also very archaic? Um, I'm not complaining, though. I don't know. I don't know if I got to the episode where I was talking about that. Uh, or maybe I got I got fi I gotta figure it out. um I gotta figure out where these episodes are. There's like six or seven. Should I uh honorable mentions or dishonorable mensions? I feel like it borders on both. because I just figured out what apparently the six seven phenomenon is. And I'm actually worried about suburban children, like, having act like, why are they saying this? Because I looked up I looked up where it came from, it came from this rapper called scrilla dude. not gonna lie. One of my personal favorites, cause I love rap, that is terrible to a certain extent. um and it is, like it's not only it's not only like it's not lyrically terrible. He's actually really good um He's actually really good whatever he's saying. I know what he's saying, which is what's terrifying that, like, apparently suburban upper middle class and upper class children are saying this. six seven thing, because it came from this video by this rapper called Skrilla do doot. Yup. and well, it's culture music, like it's it's trap culture music, it's not necessarily drill, but it's done in the style of drill. um, talking about like the culture the culture the culture um that is not necessarily like great. cause he was talking I was like yo. what the fuck are children saying this for? Um, what the fuck are children exposed to this for? Because there was no, like parental block on it or anything like that. And the dude was talking about like, straight up murderer. He was like, yeah, m, like this though. And I was like, oh no, like I I actually kind of dig his music because it's it's like it's the music that was born of like the Young Thug and the low Wayne and themehesine and it's bad. It's really bad. Like it's really bad. like if your kids are saying six seven, like, the origin of that is not, I'm like,o, shout out sc a d do, because that is facts, but also like, like like kids should not necessarily like, everything he was saying and all of his songs, I was like, that's bad. That's bad that you said that. not that you shouldn't, actually. I feel like there, like art exists as a medium to be able to have this level of freedom of speech, and that's why it exists. But also like, if you understand which I think kids obviously don't if they're just like, oh, six, seven, I'm like, okay, like, but obviously, like, this is where that came from. Like, and this is where that came from, and the dude is talking about some stuff that I'm like what? Like, I'm not confused. I know what he's talking about. But like, children should not necessarily like, even if they don't know what he's talking about, this is not like, this is different from like, when I was like, 10 and it's getting hot in here. So take off all your clothes, like that came out or like to the window to the wall, like this is mild, those things are mild, compared to like, the shit that scrill a do dude. talks about. I'm like, oh, what? What? And apparently we little kids are seeing this and exposed to it, like, they don't necessarily know what it means, but he's like, yo, these are the lyrics to my songs. Listen. I'm like, oh, like. That's troubling. That that exists. That's troubling. truly troubling. I'm I'm not talking shit. I actually really like it, but like parental controls, like, my kids should not be exposed to this, like via the Internet. Like, you should not like, this should be something especially if you live in the subrooms like if you live in a house that has rooms, like if you live in a house that has rooms in an all. like the culture that this is referencing and you know what? The only thing that actually made me look it up was like so many people were saying it in the circuit of television that I watched that I was like, it was bothering me. It was bothering me like Labubu was, but Labubu was far less disturbing, far less. I was like, oh, no. this is not cool. This is not cool, David Letterman. This is not cool, because he was like,Yo, what's up six seven? I'm like, you're 106. I don't know why you're saying this. So I looked it up. So I looked it up, and I was like, oh no, like, okay, like we know it's a cultural fucking phenomenon, but like, do you know why? Do you know why? Like, do you know why? And do you know what this man is talking about? Do you know what this man is saying? Anyway. I'm not I'm actually not gonna say it. Like I'm not gonna say it because I think it it exempt exemplifies that's what I'm trying to say right yeah. I think it exemplifies and represents a part of the culture that is deeply, deeply, deeply, deeply wrong. um in the history of the United States of America. I think it's just bad news. It's just bad news. And it's bad news, like it exists, but the reason why it exists is terrible, like it shouldn't exist is it's terrible. It's bad. It's bad and it's bad that kids are saying this. It's bad anyway. it's really bad. Anyway, I got Peloton time, bad girls' club reunion, some coffee to reheat. Here's this song, um there's no anything else for a while. I gotta make sure that like my uh I got to make sure if I get taken out, it's by like a city bus. And, you know, not just because my insides are uh imploding. um and yeah, my insides are imploding. Uh, gotta take care of number one, which is me. So, that self serving thing I get, but, you know, I'm just not the kind to to step on heads or like, I'm not gonna make it, like, purposely harder for you to do something. Like, I do believe in free will to the point where if you're not hurting anybody else, it's not affecting anybody else's, like vibe, like, do what you want, like, as long as you're not objectively or subjectively hurting anybody. Like, just don't hurt anybody, but besides this, you know, take care of yourself, but it's not, you know. I mean, you're not causing any quantifiable harm. Go ahead and, you know? I, um, but that's it. That's that's it for me. Thank you for listening. Is that it? Yeah, forget me nots. It's not finished. I've got a lot to do. Like, I actually had this is a song that actually has like a list, like a handwritten list on a piece of paper of like do this and do that and do this and do that. But like here's what I have so far just in case, you know, the city buses be getting awful close to the curb sometimes. where I stand, I am yep, they do. anyway. um I said more stories to tell and stuff, but now it's not the time or the place. did I say my thing? Yeah, I say my. Dave you were listening. something, you're listening, see you next time. That's it, yeah. Yeah, I don't have anything else. Thank you for listening. See you next time, bye.

Entre danse et théâtre, confessions et music-hall, Claire Dessimoz signe un spectacle fort sur lʹenfance, ses blessures et la confiance partagée. A voir dès 8 ans à Vidy-Lausanne jusquʹau 7 décembre, puis à Genève-ADC du 30 janvier au 1er février 2026. La chorégraphe lausannoise raconte ses "Choses graves" au micro de Thierry Sartoretti.

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 28, 2025. In this episode: 2027 Medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J's Alzheimer's asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas's Padcev's first big win in bladder cancer study. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-R4RCDF2RXVGVHPEX2WQ7A3JVKU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.In today's episode I'm joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two decades advancing cancer care, from clinical practice to leadership roles shaping strategy across Europe and Canada. Since joining Daiichi Sankyo in 2021, he has been at the forefront of one of the industry's most ambitious ADC pipelines, overseeing more than 60 clinical trials across 24 countries and driving landmark approvals that are redefining treatment in breast, lung, and gastric cancers.This week's episode is brought to you with the support of Kadans. Looking for the perfect space to grow your Life Sciences company? Kadans Science Partner is Europe's leading provider of cutting-edge lab and offices spaces, tailored to your needs. Kadans puts you at the centre of innovation, giving you the chance to connect with top researchers, universities, and investors through its international network. Here, you'll join a vibrant community of innovators driving real change. Are you ready to take your research to the next level? Learn more at kadans.com – where innovation thrives. 01:45.         Meet Markus Kosch03:12.         Clinical background shaping an industry role04:46.         Daiichi Sankyo's 40-year oncology legacy06:19.         European investments and Munich hub10:34.         ADC platform strengths explained14:20.         Key ESMO 2025 trial dataClarification: The reference to ‘TB01' at 16:24 refers to the TROPION-Breast02 clinical trial, not TB01.19:43.         Managing risks and partnerships23:35.         Patient advocacy in trial design33:59.         Future of oncology and ADCsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 oncology deals in 2025 spotlight where industry leaders are betting bigAstraZeneca and Daiichi Sankyo's Enhertu recommended for approvalTen drugs to watch in 2025: will these therapies become blockbusters?

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

Send us a textIn this episode of ADC's Parenting Adult Children podcast, host James Moffitt is joined by John Fela and Katy Moffitt to discuss the challenges and experiences of parenting children with disabilities. John shares his journey as a parent of a nonverbal autistic son, highlighting the fears and realities of finding suitable care and community for his child. Katy, with her extensive experience in special education, adds insights into the educational needs and social dynamics of children with disabilities. The conversation delves into the importance of community support, the role of churches in disability ministry, and the need for awareness and acceptance in society.Keywordsparenting, disability advocacy, autism, special education, community support, church ministry, awareness, acceptance, nonverbal communication, special needsTakeawaysJohn Fela describes himself as the 'Swiss Army knife of disability advocacy.'John's son, Chris, is nonverbal and autistic, requiring specialized care.Katy has over 25 years of experience in special education.The importance of finding a supportive community for families with disabilities.Challenges in finding suitable educational and living environments for children with disabilities.The role of churches in providing support and inclusion for families with disabilities.John emphasizes the need for awareness and acceptance in society.The fear of the future and loneliness as a parent of a child with disabilities.The significance of communication tools like TouchChat for nonverbal individuals.John's advocacy work includes writing, speaking, and creating support groups for fathers.Title OptionsNavigating Disability Advocacy with John FelaParenting Challenges: A Journey with John and KatyBuilding Community Support for Special Needs FamiliesThe Role of Churches in Disability MinistryJohn Fela: A Voice for Disability AdvocacyUnderstanding Autism: Insights from John FelaSpecial Education and Parenting: Katy's PerspectiveCreating Inclusive Communities for DisabilitiesJohn Fela's Advocacy JourneySupporting Nonverbal Communication in AutismSound bitesSwiss Army knife of disability advocacyFear of the future and lonelinessImportance of community supportRole of churches in inclusionAwareness and acceptance in societyNonverbal communication toolsChallenges in special educationBuilding support groups for fathersNavigating disability advocacyCreating inclusive communitiesChapters00:00:00 Introduction and Guest Introductions00:00:00 John Fela's Advocacy Journey00:00:00 Parenting a Nonverbal Autistic Child00:00:01 Educational and Living Challenges Listen here for our sponsors list. Many thanks to them for helping to underwrite the costs of producing this podcast. Support the showSocial Media Links https://www.youtube.com/@JamesMoffitt https://www.instagram.com/parentingadultchildren125/ https://www.tiktok.com/@chiefpropellerhead ABC's of Parenting Adult Children Facebook Page https://www.facebook.com/profile.php?id=61581576308055 r/parentingadultchildren Feel free to subscribe to these channels and share the links with your social media portals.

Esportmaníacos 2421: En el programa de hoy hemos hablado de cómo progresa el mercado europeo. Flakked dejará de ser el ADC de Team Heretics, dejando el equipo tras tres años de prestar sus servicios. Movistar KOI ha fichado a Alphari como assistant coach para reforzar el cuerpo técnico y por otro lado, tenemos muchas noticias sobre el mercado asiático, haciendo especial hincapié en T1. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:19:20 - Nerf a Neeko, ¿y a las skins de T1? 00:25:35 - ¿Renovará Doran con T1? 00:40:10 - KT Rolster podría perder a su roster 00:45:15 - Más rumores de la offseason asiática 00:56:08 - KOI Alphari 01:18:45 - Flakked deja Heretics 01:45:30 - Mikyx ofreció su proyecto a Fnatic (y le dijeron que no)

In this week's episode of Dividend Talk, we're back with a jam-packed Dividend Announcements & Earnings deep dive.We kick things off with PayPal initiating its first-ever dividend (welcome to the club, Monkey!), Hershey holding flat to stay off the aristocrat chopping block, and a wild stat on revenue-per-employee (OnlyFans crushes tech giants at $37.6M per head). Then it's over to dividend hikes from Iberdrola (+8.2%), Rockwell Automation, AbbVie, and ExxonMobil, before diving into earnings: Nestlé's volume rebound in China, Schneider Electric riding data-center tailwinds, Altria's cash-rich but growth-poor reality, UnitedHealth's margin squeeze, T. Rowe Price outflows, and Shell's $10B FCF buyback machine.In the Q&A, we tackle benchmarking vs. S&P 500, dollar-cost-averaging into falling knives, estate tax broker moves, covered-call ETFs, Finnish gems, Evolution's permanent pivot, and stock-specific takes on Novo Nordisk, APD, Qualcomm, and more.SEE YOU ON THE INSIDE!!Tickers discussed: PYPL, HSY, GOOGL, MSFT, EBAY, AMZN, IBM, MCD, IEP, IBDR.MC, MUM.DE, SIE.DE, APD, LIN, NOVO-B.CO, EVO.ST, QCOM, ARE, ADC, MO, BATS.L, PM, UNH, TROW, SHEL, XOM, TTE, ITW, ABT, ADP, SCHN.PA, ROC.AX, NOVN.SW, NESN.SW, MCD, APH, DHR, TXN, VFC, RELAS, VWS.CO, WSO, GRG.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk[Twitter] – @DividendTalk_ , @European_DG[Discord] – https://discord.gg/nJyt9KWAB5[Premium Services] – https://dividendtalk.eu/download-your-free-samples/[Malmo Meetup] – https://t.co/STgV1nMWKj

On today's episode, Dr. Tabby Khan, senior director of analytics for Komodo Health, spoke about their newest data analysis measuring age and insurance disparities in antibody-drug conjugate, or ADC, treatment rates in patients with metastatic breast cancer. The analysis was in partnership with the Tigerlily Foundation, a national breast cancer advocacy organization, in celebration of the 40th anniversary of Breast Cancer Awareness Month.

Election season is usually a time of open contests, new ambitions and fresh starts.But what happens when the gate to politics is closed  not by law, but by those in power?On Monday, October 28, 2025, veteran politician Sule Lamido arrived at the headquarters of Peoples Democratic Party in Abuja. He came prepared to purchase the nomination and expression-of-interest forms to contest for the party's national chairmanship. Instead, he walked away without them  denied access to the very entry ticket to the race.Why was Lamido shut out?What is the party's justification?And what does this shut-out tell us about democracy and internal party rule in Nigeria?This is what we are discussing in today's episode of Nigeria Daily.

Election day a moment that should define the futuretoo often turns into a market square.Whispers behind polling booths… folded notes exchanged for a quick thumbs-up…bags of rice delivered hours before the ballot box opens.Votes the very foundation of democracy are being sold to the highest bidder.But what does the law actually say about this dangerous practice?Who is breaking the law the buyer, the seller, or both?And what is being done to stop politicians from turning our votes into commodities?This is what we're discussing in today's episode of Nigeria Daily.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving Trop2-targeted therapies. This reflects the increasing focus on antibody-drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy.In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R&D capabilities in the U.S. Such strategic investments are crucial for maintaining competitive advantage and ensuring drug availability while meeting rising demands and streamlining supply chains.Turning to regulatory updates, the FDA has approved Amgen and AstraZeneca's Tezspire for chronic rhinosinusitis with nasal polyps. This marks Tezspire's second indication, following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent.In oncology, Merck's Keytruda and Astellas/Pfizer's Padcev have made headlines with compelling results in muscle-invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes.Roche has expanded the indication of its aging oncology drug Gazyva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Gazyva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas.AstraZeneca and Daiichi Sankyo's Enhertu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis' Pluvicto demonstrated promise in slowing hormone-sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology.However, not all developments have been positive. AstraZeneca faced setbacks when its Imfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the FDA.The industry is also witnessing significant advancements in next-generation ADCs, as evidenced by Tubulis' 59% response rate in early clinical trials, which has attracted substantial investor interest. Additionally, Grail's Galleri cancer blood test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices.These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences' $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development, which remains a focal point for innovative cancer therapies.Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors characterized by signSupport the show

Hear experts Matthieu Culié and Alessandro Agosti as they discuss how Olon stands out in a competitive landscape through its fully integrated end-to-end ADC manufacturing expertise, global operations, impurity control and strategic facilities.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, where key clinical trial outcomes have emerged, potentially reshaping future treatment protocols.AstraZeneca made waves with its Phase 3 trial results for Imfinzi, a PD-L1 inhibitor, in high-risk non-muscle invasive bladder cancer. The findings suggest that Imfinzi stands strong against Pfizer's PD-1 candidate, Sasanlimab. This is particularly noteworthy as bladder cancer has historically had limited non-invasive treatment options. The implications for patient care are substantial, providing hope for improved management of this form of cancer and possibly influencing treatment standards.Meanwhile, Eli Lilly's Verzenio marked another success at the ESMO Congress with its overall survival win in early breast cancer cases. This victory enhances Verzenio's standing within the CDK4/6 inhibitor class, suggesting increased adoption in clinical settings. The demonstration of extended survival benefits not only strengthens Verzenio's competitive position but also contributes to setting a new standard of care in early breast cancer treatment.On the regulatory front, Sanofi encountered mixed outcomes from the European Medicines Agency's Committee for Medicinal Products for Human Use. While Rezurock was not recommended as a third-line treatment for chronic graft-versus-host disease, this decision underscores the stringent regulatory processes companies navigate despite existing market success in other regions like the U.S.In a significant move by the FDA to expedite drug approvals, nine companies including Merck KGaA and Regeneron received priority review vouchers. These vouchers allow a shortened review timeline, reflecting an ongoing trend towards accelerating drug availability to address unmet medical needs swiftly.In terms of strategic developments, EMD Serono—Merck KGaA's U.S. branch—has unveiled a major discount initiative for its IVF treatments on the TrumpRx platform. This aligns with broader efforts to make fertility treatments more accessible amidst rising demand and economic pressures.The metabolic dysfunction-associated steatohepatitis (MASH) arena is also witnessing robust interest with over $10 billion recently reported in mergers and acquisitions. This surge indicates confidence among Big Pharma players in MASH as a lucrative therapeutic field ripe for innovation and development.In response to competitive pressures and operational challenges, Kezar Life Sciences is preparing for layoffs following the FDA's decision to cancel a critical meeting related to its R&D program. This situation illustrates the volatile dynamics within biotech firms where regulatory decisions can significantly impact corporate strategies and workforce stability.Overall, these developments reflect an industry characterized by rapid innovation, strategic realignments, and an evolving regulatory framework. The implications for patient care are substantial as these scientific advancements promise enhanced treatment options across various therapeutic areas.Switching gears to scientific developments, Bristol Myers Squibb has reported promising results from early-stage trials of its EGFRxHER3 antibody-drug conjugate. Demonstrating a 55% overall response rate, this positions BMS to potentially gain a competitive edge in the ADC market—a sector valued for targeting cancer cells while minimizing side effects on healthy tissues.Strategic partnerships continue to shape industry growth and innovation. Roche has secured a deal with Hansoh Pharmaceutical worth up to $1.45 billion for global rights to an experimental ADC outside Greater China. SimilSupport the show

This week's EYE ON NPI is as mysterious and powerful as the extra-dimensional being from Star Trek (https://en.wikipedia.org/wiki/Q_(Star_Trek)) - it's the new Arduino UNO Q (https://www.digikey.com/en/product-highlight/a/arduino/uno-q-microcontroller-board) microcontroller board, released as part of the Qualcomm/Arduino acquisition announcement (https://www.qualcomm.com/news/releases/2025/10/qualcomm-to-acquire-arduino-accelerating-developers--access-to-i). This Uno-shaped board is packed with both an STM32 microcontroller and a Qualcomm Dragonwing microprocessor so you get the best-of-both-worlds: 3.3V/5V logic compatibility with timers and ADCs, plus a full Debian install and AI support for running local vision models. We last checked in on Arduino we were reviewing their new announcements based on a partnership with Renesas: the Arduino Nano R4 SoC (https://www.youtube.com/watch?v=QLAI41ZfCfw) which is a miniaturized version of the UNO R4 (https://www.youtube.com/watch?v=uw0EU8urz5M). These boards feature an Arm microcontroller, with lots of fun on-board accessories like an LED grid, Qwiic connector, and WiFi/Bluetooth module. These boards represented a bump in capabilities over the classic UNO R3 (https://www.digikey.com/en/products/detail/arduino/A000073/3476357) but are still under-powered compared to the 'Portenta' line (https://www.digikey.com/en/products/detail/arduino/ABX00045/15294134). So, when we see the Arduino UNO Q (https://www.digikey.com/short/qc9d09fm) is a merging of three separate 'strands' of Arduino development history. One, it's shaped and has hardware-compatibility with the classic UNO which has been their mainstay for decades. Two, it has the powerful microcontroller type that the Pro line features. And three, it revives some of the Linux-based boards that Arduino had previously released like the Yun (https://www.digikey.com/en/products/detail/arduino/A000008/4486331), Tian (https://docs.arduino.cc/retired/boards/arduino-tian/) and Tre (https://docs.arduino.cc/retired/boards/arduino-tre). What sets the Q apart is that this time instead of being just a chip-supplier partnership, Arduino has been acquired as a subsidiary of Qualcomm (https://www.qualcomm.com/news/releases/2025/10/qualcomm-to-acquire-arduino-accelerating-developers--access-to-i) which means that there's going to be first-class engineering support for the onboard Dragonwing processor. Speaking of, let's take a look at the hardware included in the new Q! There's two chipsets on each board: the big processor is a Qualcomm Dragonwing™ QRB2210 (https://www.digikey.com/en/products/detail/qualcomm/QRB-2210-0-NSP752-TR-00-0/27904331) - 64-bit System-on-Chip with 4 × Arm Cortex-A53 running at 2.0 GHz and Adreno 702 GPU running at 845 MHz for 3D graphics. This chip runs mainline Debian OS with upstream support so you can configure a kernel and distribution image without needing patches. Arduino and Qualcomm distribute their own ready to go image too (https://docs.arduino.cc/tutorials/uno-q/update-image/). This chip has modern A/V support with both CSI camera and DSI MIPI display capability to match. Those high speed connects are available on the dual 60-pin bottom connects - while there isn't a sub-connect board right now, it's likely that Arduino will develop one soon. Meanwhile, you can use their documentation (https://docs.arduino.cc/hardware/uno-q/) such as STEP and Gerber files if you want to start adding a direct-plug integration into your hardware now. The second chipset is a STM32U585 Arm Cortex-M33 with 2 MB Flash, 786 kB SRAM and running at 160 MHz - it runs the Arduino Core via Zephyr OS and from the block diagram, looks like it communicates with the main core via UART and SPI. The STM is what handles GPIO, PWM, ADC, DAC, timers, etc since it is 3.3V logic and has some 5V logic-level compatibility. The main headers on the Arduino - and some of the bottom extra headers - expose the STM logic so you can connect standard sensors, OLEDs, relays etc. While there are some GPIO from the Dragonwing also available, they're 1.8V logic and are already allocated in the Linux Device tree. The Arduino UNO Q (https://www.digikey.com/short/qc9d09fm) is available for pre-order right now from DigiKey for a door-busting $44! We've already put in our order, and we'll do a project to check it out as soon as it arrives. After you get your pre-order in, check out some of the projects that have already been published to get a sense of the Q's capabilities like this MAME emulation arcade cabinet (https://projecthub.arduino.cc/jcarolinares/arduino-uno-q-arcade-cabinet-machine-39dd38) or face-recognition car (https://www.youtube.com/watch?v=EGDxAXpH_Ag). You can start dreaming of what you'll be able to do with a full computer + microcontroller board that fits where your old UNO R3 would fit, while you wait for the shipping notification.

What happens when the most complex molecules in biotech meet the organizational challenge of managing 300+ analytical scientists? The answer lies not just in the science, but in building systems that turn technical complexity into reliable delivery.In Part 2 of our deep dive with Amanda Hoertz, VP of Analytical and Formulation Sciences at KBI Biopharma, we shift focus from the molecular intricacies of ADCs to the operational mastery required to scale analytical development across multiple sites. Amanda reveals how her team achieves consistency across hundreds of scientists while maintaining the agility to pivot priorities in real time when critical programs need emergency support.This isn't just about managing people; it's about architecting systems that preserve institutional knowledge, accelerate method transfer, and deliver results when regulatory deadlines loom.What you'll discover:Seamless Project Handoffs Without Knowledge Loss: How KBI's stable team assignments eliminate the costly learning curves that plague most CDMO relationships, ensuring your molecule expertise stays with your program from development through commercial manufacturing.Organizational Scale Without Operational Chaos: The decision tree and layered reporting structure that allows 200+ analysts at a single site to function as a coordinated force, capable of rapid reprioritization and flood-level resource deployment when programs reach critical status.Digital Transformation That Actually Works: Beyond the automation buzzwords, Amanda walks through the practical realities of LIMS/ELN implementation, audit-compliant systems, and machine learning databases that transform raw data into defensible, actionable insights for complex biologics.Whether you're evaluating how analytical capabilities scale with program complexity, or seeking practical insights into leading technical teams through digital transformation, this episode delivers the operational intelligence that separates successful ADC programs from expensive failures.Connect with Amanda Hoertz:LinkedIn: www.linkedin.com/in/amanda-hoertz-3aba605KBI Biopharma: www.kbibiopharma.comKBI Portal: www.standalone.kbi.bioNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

In recent months, the People's Democratic Party (PDP) has witnessed a string of high-profile defections to the ruling All Progressives Congress (APC).From governors to lawmakers, political bigwigs are switching sides leaving many Nigerians wondering if the PDP, once Africa's largest political party, is losing its grip.Is the PDP truly on the verge of extinction, or are these defections part of a broader political realignment ahead of 2027?Join us on this episode of Nigeria Daily as we unpack the forces reshaping Nigeria's opposition politics.

Featuring an interview with Dr Laura Huppert, including the following topics: General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00) Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44) Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30) Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13) Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25) CNS penetration and activity of ADCs in the treatment of breast cancer (22:27) Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24) Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05) Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51) Ongoing evaluation of ADCs in the localized disease setting (35:42) Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38) CME information and select publications

What if the key to unlocking ADC manufacturing success lies in abandoning the platform mindset entirely?Antibody-drug conjugates represent biotech's most promising weapon against cancer: precision-targeted therapeutics that deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. But beneath the clinical promise lies a manufacturing reality that's rewriting the rules of bioprocess development, demanding analytical strategies that most CDMOs simply aren't equipped to handle.In this deep-dive episode, David Brühlmann sits down with Amanda Hoertz, Vice President of Analytical and Formulation Sciences at KBI Biopharma, where she oversees 300+ scientists across the mammalian network. Amanda's team has cracked the code on some of the industry's most challenging ADC programs, achieving a remarkable 93% batch success rate by rejecting cookie-cutter approaches in favor of molecule-specific development strategies.What you'll discover:The Platform Fallacy: Why treating ADCs like standard monoclonals is costing companies millions and months of development time, and the bespoke analytical framework that's changing everything.Cytotoxic Payload Management: From free drug analysis to employee safety protocols, Amanda reveals the hidden complexities of handling molecules designed to kill cells, including the specialized facilities and analytical methods required for GMP manufacturing.Charge Heterogeneity Mastery: The analytical method that "keeps Amanda up at night," and the development strategies her team uses to achieve robust separation and qualification across multiple sites and analysts.This episode delivers the technical depth and strategic insights that bioprocess engineers need to navigate ADC development successfully. Whether you're evaluating CDMO partnerships, optimizing analytical methods, or scaling complex conjugates, Amanda's proven strategies will transform your approach to these game-changing therapeutics.Ready to master the analytical complexities that make or break ADC programs?Connect with Amanda Hoertz:LinkedIn: www.linkedin.com/in/amanda-hoertz-3aba605KBI Biopharma: www.kbibiopharma.comKBI Portal: www.standalone.kbi.bioNext step:Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

Synopsis: Few biotechs can pull off what Syndax Pharmaceuticals has achieved — two first-in-class oncology drug launches, built entirely through strategic in-licensing and disciplined execution. In this episode, host Alok Tayi sits down with Michael Metzger, Chief Executive Officer of Syndax, to explore how the company identified breakthrough assets, advanced them through development, and successfully commercialized them within a span of just a few years. Metzger unpacks Syndax's distinctive model — leveraging external innovation, rapid clinical validation, and precision in go-to-market strategy — to create measurable patient and shareholder value. From the first menin inhibitor approved in acute leukemia to a novel CSF1R antibody reshaping GVHD and fibrosis care, Syndax's portfolio embodies science that scales. The conversation offers an insider's perspective on risk management, deal-making, data-driven decision-making, and why speed to market has become the new differentiator in biotech. A must-listen for investors, executives, and founders navigating the complexities of growth in a capital-intensive industry. Biography: Michael A. Metzger is a seasoned biopharmaceutical executive with extensive leadership experience in company building, operations, and strategic transactions across the life sciences industry. He currently serves as the Chief Executive Officer of Syndax Pharmaceuticals, a publicly traded oncology company, a role he assumed in 2022. Prior to this, Michael served as President and Chief Operating Officer of Syndax from 2015 and has been a member of the company's Board of Directors since 2019. Previously, Michael held leadership roles at Regado Biosciences, Inc, where he served as President and CEO and guided the company through a successful merger with Tobira Therapeutics. He also served as Executive Vice President and COO at Mersana Therapeutics, Inc., where he oversaw key strategic initiatives in ADC development for oncology. Earlier in his career, Michael held senior roles in business development and M&A at Forest Laboratories, LLC, contributing to its transformation ahead of its acquisition by Allergan plc. He also held leadership positions at Onconova Therapeutics, Inc., and was a Managing Director at MESA Partners, Inc., a healthcare-focused venture capital firm. Michael has served on several public and private company boards, including CTI BioPharma Corp., acquired by SOBI AB in 2023, and continues to be active in guiding innovative biotech organizations. Michael holds a B.A. from George Washington University and a M.B.A. in Finance from the NYU Stern School of Business.

In this episode of the Mic On Podcast, the host, Seun Okinbaloye, speaks with former Senior Political Assistant to Atiku Abubakar, Demola Olarewaju about Nigeria's 2027 political landscape.Mr Olarewaju, who resigned from the PDP, says the party is “no longer fit for purpose” and pitches the ADC as the real opposition force, especially on a potential Atiku–Obi ticket. He calls Tinubu a “political strategist” but says the president is beatable if opposition groups unite.On Lagos politics, Mr Olarewaju rejected the talk of Seyi Tinubu's governorship ambition, arguing that the state needs inclusive leadership beyond oligarch families.Guest:Mr Demola OlarewajuSenior Political Assistant to Atiku Abubakar

We break down Pobelter's thoughts on the ADC role and discuss how OP support is.Join an academy for coaching and guides: https://wtl.lol/thinkchallJoin our free community with courses: https://wtl.lol/skool

Featuring an interview with Prof Peter Schmid, including the following topics: Response to immunotherapy in breast cancer subtypes (0:00) Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51) Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03) ADC structure and treatment-related adverse events (19:02) Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06) Novel ADCs and bispecific antibodies under investigation for mBC (28:30) Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01) Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06) CME information and select publications

In this episode of the Mic On Podcast, Seun Okinbaloye sits with former Kogi State Deputy Governor Edward Onoja, who opens up on his political journey, his rift with ex-Governor Yahaya Bello, and his role in national politics.Onoja recalls Bello urging him to contest the 2023 primaries only to withdraw support at the last minute, a move he calls “shocking” but says he has forgiven. He defends the Bello administration's record in Kogi, from civil service reforms to new hospitals and institutions, while stressing that he takes “credit and blame” for its legacy.In national politics, Onoja dismisses claims of northern resentment toward Tinubu, calling himself a “foot soldier” for the president's reelection and pledging to build unity even with opposition figures. But he waves off coalition parties like the ADC as unserious, insisting his loyalty rests with the APC.Guest:Chief Edward Onoja(Former Deputy Governor, Kogi State / Governing Member, South East Development Commission)

Send us a textPeaches and Aaron are back swinging at the nonsense. From Special Warfare's assessment model to Air Force Academy cadets racking up predatory loans, this episode rips into leadership fails, lazy commanders who hand out paperwork like candy, and the lost art of spot corrections. We go from stories of LOCs, LORs, and mustache games with Rangers, to watching Army football drop a quarter million dollars just to get smoked by Tarleton State. Oh, and Peaches gets dragged through camp in just a towel because Rangers can't handle beards. Add in college football meltdowns, fantasy league punishments, and some blistering hot takes on what “leadership” actually means—you've got a mix of cringe, comedy, and brutal honesty that only Ones Ready delivers.⏱️ Timestamps: 00:00 – Intro & Special Warfare assessment truth bombs 01:15 – Operator Training Summit Nashville & gear talk 03:10 – Booties in the pool: stop training slick 04:45 – AOCs gone wild with paperwork 07:00 – Progressive discipline vs lazy leadership 10:20 – Why real mentorship beats LOR inflation 12:50 – Spot corrections, life problems, and actually helping airmen 17:30 – Setting boundaries and predictable leadership 23:10 – Smoke sessions, “don't tell dad,” and better discipline tools 25:30 – Peaches' LOC story that turned his career around 29:30 – Pushing boundaries vs working the system 33:00 – Rangers, beards, and the towel walk of shame 36:00 – Mustache game rules and how to win (or lose) 40:00 – Always rebuttal your paperwork (and call ADC, not your buddy) 41:30 – The insane $416K Academy disenrollment bill 47:00 – The infamous Manitou Incline & OTS candidate pain fest 54:00 – Army football pays $250K to lose to Tarleton State 56:10 – Air Force uniforms: actually fire this year 01:02:00 – Bama gets stomped, SEC fan tears taste delicious 01:03:50 – Peaches unveils the Fantasy Loser Belt 01:04:55 – Wrap up & call-to-actions

Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract  Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.  Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).

Have you ever felt the presence of a loved one after they passed? Was it just your imagination… or could it have been a sacred message from the other side? In this soul-stirring episode of The Abundance Journey, Elaine welcomes the radiant and deeply wise Purnima Sinha, a wellness and spiritual life coach with over 50 years of meditation practice and profound experience in after-death communication, mystical encounters, and soul-to-soul connection. Together, Elaine and Purnima explore:· How to recognize signs and messages from loved ones who have crossed over· Why intention and energy are the keys to unlocking Divine guidance· The role of self-love, forgiveness, and surrender in profound healing· How grief, loss, and even pain can become portals to spiritual connection and abundance This conversation will remind you that love never dies, that you are always supported, and that the Divine is inviting you into a deeper partnership with every breath. About the Guest:(bio, personal links, resource links)Purnima has been trained in Ultra Transcendental Meditation- Surat Shabd Yoga. Purnima practiced meditation for over 50 years. Purnima does private sessions. Purnima has Certificates in LifeStyle Medicine and Meditation & Psychotherapy from the Harvard School of Medicine in Boston. Purnima has presented in IANDS conference a few times and is part of Healing Circle also.Purnima has worked in the healthcare system and county wellness program since 2009 as a Wellness and Meditation/Spiritual Life Coach. Purnima has ADC, OBE, STE, Mystical experiences and shared death experiences all her life. Purnima has helped many patients during their transition. She has been interviewed by JeffMara podcast about after-death communication and an IANDS podcast by Betty Guadagno about ADC how to Let Go Finally. Purnima's article got published in Eckhart Tolle (Power Of NOW and A New Earth) newsletter about healing.Her motto is Self Care = Self LoveAbout the Host, Elaine Starling: (bio, personal links, resource links)An international TEDx speaker, bestselling author, coach and mentor, Elaine Starling is recognized for her video show and podcast, The Abundance Journey. Known as The Abundance Ambassador, Elaine helps high-achieving women stop proving and start receiving by aligning with Divine guidance. Through her coaching, podcast, and The Soul Aligned Life Process™, Elaine empowers women to embody their worth, speak their truth, and create deeply fulfilling relationships—from the inside out.Elaine Starling Social Media Links:Facebook: https://www.facebook.com/elaine.abundance Linkedin: https://www.linkedin.com/in/elainestarling/YouTube: https://www.youtube.com/channel/UC3eXgwdMYYzLicCEcB1DdrgTEDx Talk, “Abundance Is a Choice” https://youtu.be/tMQ0D4sfEysWebsite: www.TheAbundanceJourney.com5 Steps to Activate Your Abundance Universal Book Link:

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.

@phoenix_agenda and @nigeriasbest had a one to one chat after a long summer break.They discussed:1. President Tinubu's trips to Brazil and Japan.2. Wike says Rivers State of Emergency should end 18th September 3. INEC begins Continuous Voter Registration exercise4. President Tinubu goes to Europe on 10 day Annual Leave 5. Attack on Gbadebo Rhodes-Vivour's defection ceremony to ADC

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Cet épisode est présenté par Squarespace.La plateforme tout-en-un pour créer un site élégant et professionnel, même sans compétences techniques.Templates au design impeccable, outils puissants, et un assistant IA qui simplifie tout.Essayez gratuitement 14 jours et profitez de -10 % avec le code BOLD sur squarespace.com/BOLD.

Welcome back to The Dive Driven by Kia! Kobe, Azael and Meteos look ahead to 4 more years of T1 Faker before breaking down 4 opening week sweeps in the LTA North. After the break, we look ahead to this weekend's matchups as chosen by the teams themselves. Finally, Patch 25.15 is live! The crew discusses Braum nerfs, the state of ADC and more.Timestamps:0:00 - Intro & Faker Re-signs to T18:15 - Travis Gafford Steps Away12:37 - LTA Split 3 Format17:13 - Team Liquid vs 100 Thieves Review34:23 - Shopify Rebellion vs Dignitas Review45:21 - Cloud9 vs Lyon Review53:51 - FlyQuest vs Disguised Review1:01:56 - Week 2 Matches Preview1:11:18 - Patch 25.151:19:48 - ADC & Balance Debate 

Welcome back to another episode of The Dive Driven by Kia. Champion designer Riot Yelough joins Kobe and Meteos to give some behind-the-scenes intel on the new ADC champ Yunara. Kobe pitches us on his Yunara build (Hullbreaker, Hexplate, Hurricane) and we go over expectations for Yunara in pro play. Will we see Yunara on the LTA stage this weekend? Plus, we break down Patch 25.14, 100 Thieves' last dance, LTA North roster changes and power rankings for Split 3.Finally, make sure to grab tickets for LTA Split 3! Tickets are still available for Opening Week and throughout the entire split, including the LTA Championship in Texas. This Saturday at the Riot Games Arena in LA enjoy a Spirit Blossom themed Opening Day tailgate after the games where you can get a free Spirit Blossom Teemo skin, win prizes, buy some merch (including the exclusive LTA Poro), meet the teams, enjoy free food and more!Purchase your tickets for LTA's Split 3 here: https://www.tixr.com/groups/ltanorth/events/2025-lta-north-split-3-mastercard-opening-week-day-1-150643And get your tickets to the LTA Championship here: https://www.ticketmaster.com/league-of-legends-tickets/artist/2144001Timestamps:0:00 - Introduction with Yunara's Designer Riot Yelough4:54 - Initial Reactions with Yunara's Launch13:23 - Yunara's Itemization22:57 - Thoughts on Yunara in Pro Play33:38 - Evolution of Skill Expression37:57 - Favorite Moments from MSI41:50 - Fantasy is Back42:58 - Patch 25.1455:23 - 100T's Exit from the LTA1:04:53 - LTA Roster Changes1:21:29 - Power Rankings